David Alan Rizzieri | Scholars@Duke

David Alan Rizzieri
Professor of Medicine

My research interests focus on the care of patients with hematologic malignancies, both with and without the use of bone marrow or stem cell transplantation. I focus my research efforts on new approaches to manipulate minimal residual disease.

Recent endeavors have included:

Phase one trials with novel anti-cancer agents targeting aurora kinases, tyrosine kinases, mtor, VEGF, and raf/ras pathways
New monoclonal antibodies targeting tumor stroma rather than cellular antigens
Investigating new antibody targets, i.e. CD123, endoglin, or tenascin for hematologic malignancies
Aggressive therapy and transplantation for mantle cell lymphoma
Antiangiogenesis therapy for patients with NHL
Nonablative allogeneic transplantation therapy with matched or mismatched donors followed by immune modulation

Current Appointments & Affiliations

Professor of Medicine, Medicine, Cellular Therapy, Medicine 2013
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1994

Contact Information

1149 N Pavilion, Durham, NC 27710
Box 3961 Med Ctr, Durham, NC 27710
david.rizzieri@dm.duke.edu (919) 668-1040

Background
Education, Training, & Certifications
- Fellow In Hematology/Oncology, Medicine, Duke University 1994 - 1997
- Medical Resident, Medicine, Duke University 1991 - 1994
- M.D., University of Rochester 1991
Duke Appointment History
- Associate Professor of Medicine, Medicine, Cellular Therapy, Medicine 2007 - 2013
- Associate Professor of Medicine, Medicine, Cellular Therapy, Medicine 2003 - 2007
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 1998 - 2003
- Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1997 - 1998
Research
Selected Grants
- AG-120 awarded by Agios Pharmaceuticals, Inc. 2017 - 2022
- Venetoclax (ABT-199/GDC-0199) in combination with Azacitidine awarded by AbbVie Inc. 2017 - 2022
- Phase I/II Study of Lintuzumab-Ac225 AML awarded by Actinium Pharmaceuticals, Inc. 2017 - 2022
- A Phase 3 Multicenter, Randomized, Open Label study of Guadecitabine awarded by Astex Therapeutics Ltd. 2017 - 2022
- Postdoctoral training in genomic medicine research awarded by National Institutes of Health 2017 - 2022
- Phase 1 Study of ABBV-075 awarded by AbbVie Inc. 2017 - 2022
- Phase 3 Guadecitabine (SGI-110-07) awarded by Astex Therapeutics Ltd. 2017 - 2021
- Phase I study of ADCT-301 in CD25+ AML awarded by ADC Therapeutics Sarl 2016 - 2021
- Phase 2 of SY-1425 awarded by SYROS PHARMACEUTICALS 2016 - 2021
- Efficacy study of Inecalitol in combination with Decitabine in Acute Myeloid Patients unfit for standard chemotherapy awarded by Hybrigenics 2016 - 2021
- Randomized Phase II study of CX-01 combined with standard induction therapy for newly diagnosed AML awarded by Cantex Pharmaceuticals, Inc. 2016 - 2021
- Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
- A phase 3 study of SGI-110 vs Treatment Choice for AML patients not candidates for chemotherapy awarded by Astex Therapeutics Ltd. 2016 - 2020
- Phase III study of ASP2215 vs Salvage Chemo in pts with R/R AML with FLT3 mutation awarded by Astellas Pharma Global Development, Inc 2016 - 2020
- Quizartinib AC220-007 awarded by Ambit Biosciences 2015 - 2020
- AC220-A-U302 trial awarded by Daiichi Sankyo Inc 2016 - 2020
- Phase 1/1b, First-in-Human FLX925 for R/R AML awarded by Flexus Biosciences, Inc 2015 - 2020
- Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD awarded by National Institutes of Health 2015 - 2020
- Phase II study of SINE (KPT-330) vs SOC in patients with R/R AML awarded by Karyopharm Therapeutics 2015 - 2020
- A Phase 1 Dose Escalation Study of MDG006 in Patients with Relapsed or Refractory AML awarded by MacroGenics, Inc. 2015 - 2020
- Stemline Phase II awarded by Stemline Therapeutics, Inc 2015 - 2020
- A Multicenter Phase III Rand, open-Label, study of Bosutinib vs Imatinib in adults with newly diagnosed CPCML awarded by Pfizer, Inc. 2014 - 2019
- Phase I Study of ABT-199 in comb w/ Aza or Dec with AML patients ho are > 65 y/o awarded by AbbVie Inc. 2014 - 2019
- Phase 2, Randomized, Double-Blind, Placebo-Controlled study of Azacitidine with or without Birinapant awarded by Novella Clinical 2014 - 2019
- Phase I/II Pri-724 for Advanced Myeloid Malignancies awarded by PRISM Pharma Co., Ltd 2014 - 2019
- SL-401 with AML patients awarded by Stemline Therapeutics, Inc 2014 - 2019
- Phase I study of L-asparaginase encapsulated in red blood cells (ERYASP) awarded by ERYTECH Pharma 2014 - 2019
- Development of the Phase I study involving ET190L1-Artemis in CD19 positive blood malignancies awarded by Eureka Therapeutics, Inc. 2016 - 2018
- Improving Outcomes of Older and Medically Infirm Patients with AML awarded by Fred Hutchinson Cancer Research Center 2015 - 2017
- Kalobios Ph1/2 KB004 for EphA3-Expressing Hematologic Malignancies (KB004-01) awarded by KaloBios Pharmaceuticals, Inc 2015 - 2016
- Cancer Biology Training Grant awarded by National Cancer Institute 1993 - 2016
- Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
- Mechanisms of lung injury following autologous BMT awarded by National Institutes of Health 2003 - 2007
- Mentored Patient-Oriented Research Career Dev Award awarded by National Institutes of Health 2000 - 2005
Publications & Artistic Works
Selected Publications
- Conference Papers
  - Stephens, SJ, Thomas, S, Rizzieri, DA, Horwitz, ME, Chao, NJ, Engemann, AM, Lassiter, M, and Kelsey, CR. "Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity." October 2016. Full Text
  - Huang, L-W, Bacon, W, Cirrincione, C, Peterson, B, Long, GD, Rizzieri, DA, Horwitz, ME, Sullivan, K, Corbet, K, Chao, NJ, Gasparetto, C, and Tuchman, S. "Efficacy of Autologous Stem Cell Transplantation in Older Multiple Myeloma Patients." March 2016. Link to Item
  - Muffly, L, Pasquini, MC, Martens, M, Brazauskas, R, Zhu, X, Adekola, K, Aljurf, MD, Artz, AS, Bajel, A, Ballen, KK, Battiwalla, M, Beitinjaneh, A, Cahn, J-Y, Carabasi, M, Chen, Y-B, Chhabra, S, Ciurea, SO, Copelan, EA, D'Souza, A, Edwards, J, Freytes, CO, Fung, HC, Gale, RP, Giralt, SA, Hashmi, SK, Hematti, P, Hildebrandt, GC, Ho, VT, Jakubowski, AA, Lazarus, HM, McCarthy, PL, Olin, RL, Olsson, R, Rezvani, A, Rizzieri, DA, Seftel, M, Seo, S, Sorror, ML, Szer, J, and Wood, WA. "Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes." March 2016. Link to Item
  - Rizzieri, DA, Rao, AV, Beaven, A, Brander, D, DeCastro, C, Diehl, L, LeBlanc, TW, Long, GD, McKinney, M, Toaso, B, Chao, NJ, and Sung, AD. "Clinical and Immunomodulatiory Outcomes of Microtransplantation for AML." March 2016. Link to Item
  - Advani, AS, Tse, W, Jia, X, Elson, P, Cooper, B, Ali-Osman, F, Park, J, Rao, AV, Rizzieri, DA, Wang, ES, Cotta, CV, Kalaycio, M, Sobecks, RM, Rouphail, B, Maciejewski, JP, Fensterl, J, Bailey, L, Carew, JS, Foster, B, Rush, ML, Adams, D, Griffiths, EA, and Sekeres, MA. "Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)." December 3, 2015. Link to Item
  - Berdeja, JG, Heinrich, M, Dakhil, S, Goldberg, SL, Wadleigh, M, Catchatourian, R, Kuriakose, P, Cortes, JE, Radich, JP, Rizzieri, DA, Bonifacio, G, Dautaj, I, Warsi, G, and Mauro, MJ. "ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)." December 3, 2015. Link to Item
  - Gasparetto, C, Green, M, Srinivasan, A, Kang, Y, Rizzieri, DA, Decastro, C, Diehl, LF, Beaven, A, Li, Z, Rao, AV, Garrett, A, Tuchman, S, and Long, GD. "A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma." December 3, 2015. Link to Item
  - Poe, JC, Jia, W, Li, Z, Hakim, FT, Pavletic, SZ, Rose, JJ, Rizzieri, DA, Yang, Y, Chen, BJ, Green, M, Anand, S, Siebel, CW, Maillard, I, Chao, NJ, and Sarantopoulos, S. "Targeting the Human Notch 2-BCR Axis: A Driver of B-Cell Hyper-Responsiveness in Active Chronic Graft-Versus Host Disease (cGVHD)." December 3, 2015. Link to Item
  - Stein, EM, Garcia-Manero, G, Rizzieri, DA, Tibes, R, Berdeja, JG, Jongen-Lavrencic, M, Altman, JK, Dohner, H, Thomson, B, Blakemore, SJ, Daigle, S, Fine, G, Waters, NJ, Krivstov, AV, Koche, R, Armstrong, SA, Ho, PT, Lowenberg, B, and Tallman, MS. "A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition." December 3, 2015. Link to Item
  - Sweet, KL, Pemmaraju, N, Lane, AA, Stein, AS, Vasu, S, Blum, W, Rizzieri, DA, Wang, ES, Rowinsky, EK, Szarek, M, Brooks, CL, Disalvatore, S, Liu, D, Duvic, M, Schwartz, JD, and Konopleva, M. "Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)." December 3, 2015. Link to Item
  - Brander, DM, Allgood, SD, Rizzieri, DA, Stewart, T, Weinberg, JB, and Lanasa, MC. "Final Clinical Results with Laboratory Correlates in the Phase I Trial of Lenalidomide Plus Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)." December 6, 2014. Link to Item
  - Mauro, MJ, Dakhil, S, Cortes, JE, Rizzieri, DA, Keir, CH, Yi, S, Heinrich, MC, Goldberg, SL, Catchatourian, R, Kuriakose, P, and Radich, JP. "Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update." December 6, 2014. Link to Item
  - Advani, A, Cooper, B, Sowunmi, O, Elson, P, Ali-Osman, F, Park, J, Rao, A, Rizzieri, DA, Wang, ES, Cotta, C, Sekeres, MA, Kalaycio, M, Sobecks, R, Rouphail, B, Maciejewski, JP, Davis, R, Bailey, L, Foster, B, Rush, ML, Adams, D, and Tse, W. "A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML)." November 16, 2012. Link to Item
  - Brander, DM, Beaven, AW, Gockerman, JP, Diehl, LF, Gasparetto, C, Shea, TC, deCastro, C, Moore, JO, and Rizzieri, DA. "Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma." November 16, 2012. Link to Item
  - Kantarjian, HM, Roboz, GJ, Rizzieri, DA, Stock, W, O'Connell, CL, Griffiths, EA, Yee, K, Tibes, R, Garcia-Manero, G, Ravandi, F, Walsh, K, Feldman, E, Ritchie, E, Rao, A, Decastro, C, Schimmer, AD, Mesa, RA, Syed, I, Choy, G, Oganesian, A, Taverna, P, Azab, M, Chung, W, and Issa, J-P. "Results From the Dose Escalation Phase of a Randomized Phase 1-2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML." November 16, 2012. Link to Item
  - Konopleva, M, Hogge, DE, Rizzieri, DA, Cirrito, TP, Kornblau, SM, Borthakur, G, Bivins, C, Garcia-Manero, G, Kadia, TM, Ravandi, F, Andreeff, M, Cortes, JE, Hoberman, K, Szarek, M, Rowinsky, E, Bergstein, I, Kantarjian, HM, and Frankel, AE. "SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML." November 16, 2012. Link to Item
  - Love, CL, Jima, D, Sun, Z, Miles, RR, Dunphy, CH, Choi, WWL, Au, WY, Srivastava, G, Lugar, P, Rizzieri, DA, Lagoo, AS, Bernal-Mizrachi, L, Mann, KP, Flowers, CR, Naresh, K, Evens, AM, Chadburn, A, Gordon, LI, Czader, M, Gill, J, Hsi, ED, Zhang, J, Grubor, V, Levy, S, Bunerjee, A, Dunson, D, Li, G, Moffitt, A, Greenough, A, McKinney, MS, and Dave, SS. "ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom." November 16, 2012. Link to Item
  - Rao, A, Khan, G, Rizzieri, DA, Moore, JO, Gockerman, JP, Diehl, LF, Beaven, AW, Adams, D, Warzecho, J, and Decastro, C. "Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS." November 16, 2012. Link to Item
  - Rao, A, Rizzieri, DA, Vanegas, E, Moore, JO, Gockerman, JP, Diehl, LF, Adams, D, Warzecho, J, and Decastro, C. "Pilot Study of Sorafenib for Myelodysplastic Syndrome." November 16, 2012. Link to Item
  - Rizzieri, DA, Vey, N, Thomas, X, Huguet, F, Schlenk, RF, Krauter, J, Kindler, T, Gjertsen, B, Blau, IW, Johansen, M, Bergeland, T, Gianella-Borradori, A, Jacobsen, TF, Rao, J, and Krug, U. "A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline." November 16, 2012. Link to Item
  - Kanda, J, Kaynar, L, Kanda, Y, Prasad, VK, Parikh, SH, Rizzieri, DA, Long, GD, Sullivan, KM, Gasparetto, C, Chute, JP, Morris, A, Winkel, S, McPherson, J, Kurtzberg, J, Chao, NJ, and Horwitz, ME. "USE OF CYCLOSPORINE IS ASSOCIATED WITH THE INCREASE IN PRE-ENGRAFTMENT SYNDROME AFTER MYELOABLATIVE DUAL CORD BLOOD TRANSPLANTATION." February 2012. Link to Item
  - Bacon, WA, Long, GD, Rizzieri, DA, Horwitz, ME, Chute, JP, Sullivan, KM, Yopp, A, Johns, A, Chao, NJ, and Gasparetto, C. "Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma." November 18, 2011. Link to Item
  - Beaven, AW, Rizzieri, DA, Powell, Z, Li, Z, Alton, P, Warzecho, J, Diehl, LF, Moore, JO, III, DCCM, and Gockerman, JP. "High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma." November 18, 2011. Link to Item
  - Cortes, JE, Feldman, EJ, Goldberg, SL, Rizzieri, DA, Louie, AC, and Kolitz, JE. "Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients." November 18, 2011. Link to Item
  - Cortes, JE, Feldman, EJ, Goldberg, SL, Rizzieri, DA, Paulsen, KH, Louie, AC, and Kolitz, JE. "CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in '65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report." November 18, 2011. Link to Item
  - Cortes, JE, Feldman, EJ, Yee, K, Rizzieri, DA, Advani, AS, Charman, A, Toal, MJ, and Kantarjian, HM. "Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia." November 18, 2011. Link to Item
  - Gasparetto, C, Bacon, WA, Doan, P, Rizzieri, DA, Horwitz, ME, Chute, JP, Sullivan, KM, Yopp, A, Li, Z, Chao, NJ, and Long, GD. "High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation." November 18, 2011. Link to Item
  - Kanda, J, Rizzieri, DA, Long, GD, Gasparetto, C, Chute, JP, Sullivan, KM, Morris, A, McPherson, J, Livingston, JA, Broadwater, G, Niedzwiecki, D, Chao, NJ, and Horwitz, ME. "The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation." November 18, 2011. Link to Item
  - Lim, S, Saw, TY, Chang, S, Zhang, M, Janes, MR, Fruman, DA, Rizzieri, DA, Tan, S-Y, Chuah, C, and Ong, ST. "Targeting of a Novel MNK-eIF4E-b-Catenin Axis in Blast Crisis Chronic Myelogenous Leukemia Inhibits Leukemia Stem Cell Function." November 18, 2011. Link to Item
  - Love, CL, Jima, D, Zhang, J, Grubor, V, Miles, RR, Dunphy, CH, Richards, KL, Choi, WWL, Au, WY, Srivastava, G, Chadburn, A, Gordon, LI, Evens, AM, Hsi, ED, Czader, M, Rizzieri, DA, Lagoo, AS, Bernal-Mizrachi, L, Mann, KP, Sunay, S, Flowers, CR, Naresh, K, Thompson, MA, Gill, J, and Dave, SS. "Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma." November 18, 2011. Link to Item
  - Morris, TA, Rizzieri, DA, de Castro, CM, Diehl, LF, Gockerman, JP, Lagoo, AS, Moore, JO, and Rao, AV. "Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia." November 18, 2011. Link to Item
  - Rizzieri, DA, Vey, N, Schlenk, RF, Thomas, X, Huguet, F, Gjertsen, B, Krauter, J, Blau, IW, Johansen, M, Gianelli-Borradori, A, Jacobsen, TF, Rao, J, and Krug, U. "A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response." November 18, 2011. Link to Item
  - Kanda, J, Horwitz, ME, Long, GD, Gasparetto, C, Sullivan, KM, Chute, JP, Morris, A, Hennig, T, Chao, NJ, and Rizzieri, DA. "OUTCOMES OF A 1-DAY NONMYELOABLATIVE PREPARATIVE REGIMEN FOR PRIMARY GRAFT FAILURE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION." February 2011. Full Text Link to Item
  - Hutchinson, CB, Crow, JH, Huang, Q, Lu, CM, Sebastain, S, Rehder, C, Lagoo, AS, Goodman, B, Horwitz, ME, Rizzieri, DA, Datto, M, Buckley, P, and Wang, E. "Donor Cell Leukemia: A Clinicopathological Study of 9 Cases and a Comprehensive Review of Literature." November 19, 2010. Link to Item
  - Jacobs, CL, Patel, A, Jima, D, Liu, Q, Greenough, A, Zhang, J, Dunphy, C, Richards, K, Choi, W, Srivastava, G, Au, WY, Evens, AM, Gordon, LI, Czader, M, Rizzieri, DA, Lagoo, AS, Mann, KP, Flowers, CR, Bernal-Mizrachi, L, Naresh, K, Luftig, M, Chadburn, A, Hsi, E, Thompson, MA, Gill, J, and Dave, S. "Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma." November 19, 2010. Link to Item
  - Kanda, J, Long, GD, Gasparetto, C, Horwitz, ME, Sullivan, KM, Chute, JP, Morris, A, Li, Z, Chao, NJ, and Rizzieri, DA. "Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies." November 19, 2010. Link to Item
  - Kanda, J, Rizzieri, DA, Gasparetto, C, Long, GD, Chute, JP, Sullivan, KM, Morris, A, Smith, CA, Hogge, DE, Nitta, J, Song, K, Niedzwiecki, D, Chao, NJ, and Horwitz, ME. "Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning." November 19, 2010. Link to Item
  - Konopleva, M, Hogge, DE, Rizzieri, DA, Cirrito, TP, Liu, JS, Kornblau, SM, Grable, M, Hwang, I-R, Borthakur, G, Mankin, A, Bivins, C, Garcia-Manero, G, Kadia, T, Harris, D, Ravandi, F, Andreeff, M, Cortes, JE, Niecestro, R, Bergstein, I, Kantarjian, HM, and Frankel, AE. "Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS." November 19, 2010. Link to Item
  - Lancet, JE, Smith, BD, Bradley, R, Komrokji, RS, Teofilovici, F, and Rizzieri, DA. "A Phase I/II Trial of the Potent Hsp90 Inhibitor STA-9090 Administered Once Weekly In Patients with Advanced Hematologic Malignancies." November 19, 2010. Link to Item
  - Pettengell, R, Zinzani, PL, Narayanan, G, de Mendoza, FH, Digumarti, R, Gomez, H, Coiffier, B, Schiller, G, Rizzieri, DA, Cernohous, P, Wang, L, and Singer, J. "Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results." November 19, 2010. Link to Item
  - Rizzieri, DA, Johnson, JL, Byrd, JC, Lozanski, G, Powell, BL, Shea, TC, Nattom, S, Hoke, E, Cheson, BD, and Larson, R. "Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002." November 19, 2010. Link to Item
  - Downie, BJ, Erba, HP, Stone, RM, Rizzieri, DA, and Foran, JM. "Monosomal Karyotype Is Predictive of Poor Response to Therapy and Worse Overall Survival in Secondary Acute Myeloid Leukemia (sAML); Analysis of a Multi-Center Phase II Study of Amonafide and Cytarabine Induction Therapy." November 20, 2009. Link to Item
  - Erba, HP, O'Donnell, M, Allen, SL, Baer, MR, Powell, BL, Stone, RM, Bennett, JM, Lundberg, AS, Capizzi, RL, and Rizzieri, DA. "Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study." November 20, 2009. Link to Item
  - Jacobs, CL, Jima, DD, Zhang, J, Dunphy, C, Richards, KL, Choi, WWL, Srivastava, G, Evens, AM, Gordon, LI, Czader, M, Rizzieri, DA, Lagoo, AS, Mann, KP, Flowers, CR, Naresh, K, Luftig, M, Friedman, DR, Weinberg, JB, Thompson, MA, Gill, J, Kahl, BS, Chadburn, A, and Dave, S. "A Comprehensive Identification of the Microrna Transcriptome and Its Application in B Cell Malignancies." November 20, 2009. Link to Item
  - Lanasa, MC, Davis, PH, Datto, M, Cook, H, and Rizzieri, DA. "Cenersen, An Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab Shows Clinical Activity in High Risk CLL." November 20, 2009. Link to Item
  - Lancet, JE, Komrokji, RS, Lin, H, de Castro, CM, Rizzieri, DA, Melchert, M, and List, AF. "Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission." November 20, 2009. Link to Item
  - Nicolini, FE, Kim, D-W, Ceglarek, B, Turkina, A, Alimena, G, Al-Ali, HK, Shen, Z, Jootar, S, Smith, G, De Souza, CA, Dorlhiac-Llacer, PE, Rizzieri, DA, Szczudlo, T, Berton, M, Wang, J, Bieri, C, and le Coutre, PD. "Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study." November 20, 2009. Link to Item
  - O'Brien, S, Rizzieri, DA, Vey, N, Ravandi, F, Krug, UO, Sekeres, MA, Dennis, M, Venditti, A, Jacobsen, TF, Staudacher, K, Nilsson, BI, and Giles, FJ. "A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML." November 20, 2009. Link to Item
  - Pettengell, R, Coiffier, B, Narayanan, G, Hurtado de Mendoza, F, Digumarti, R, Gomez, H, Zinzani, PL, Schiller, GJ, Rizzieri, DA, Cernohous, P, Wang, L, and Singer, JW. "Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL)." November 20, 2009. Link to Item
  - Powell, BL, Khoury, HJ, Lipton, JH, Rizzieri, DA, Williams, D, and Turner, AR. "Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials)." November 20, 2009. Link to Item
  - Smith, JL, Patel, A, Fan, S, Jacobs, CL, Walsh, KJ, Liu, Q, Rizzieri, DA, and Dave, S. "Histone Deacetylase Inhibition Using LBH589 Is Effective in Lymphoma and Results in Down-Regulation of the NF-KB Pathway." November 20, 2009. Link to Item
  - Tran, TN, Ray, GT, Saddier, P, Trigg, M, Hayes, N, Li, Y, Rizzieri, DA, Stein, A, Weber, D, Serody, J, Raasch, R, and Habel, L. "Immunocompromised Status of Patients with Hematologic and Solid Tumor Malignancies: Construction of a Practical Algorithm." November 20, 2009. Link to Item
  - Walsh, KJ, Fan, S, Patel, A, Jacobs, CL, Smith, JL, Liu, Q, Rizzieri, DA, and Dave, S. "PI3K Inhibitors Inhibit Lymphoma Growth by Downregulation of MYC-Dependent Proliferation." November 20, 2009. Link to Item
  - le Coutre, PD, Ceglarek, B, Turkina, A, Kim, D-W, Alimena, G, Al-Ali, HK, Shen, Z, Jootar, S, Smith, G, De Souza, CA, Rizzieri, DA, Szczudlo, T, Berton, M, Wang, J, Dial, E, and Nicolini, FE. "Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study." November 20, 2009. Link to Item
  - le Coutre, PD, Turkina, A, Kim, D-W, Ceglarek, B, Alimena, G, Al-Ali, HK, Shen, Z, Jootar, S, Smith, G, De Souza, CA, Dorlhiac-Llacer, PE, Rizzieri, DA, Szczudlo, T, Berton, M, Wang, J, Wang, S-T, and Nicolini, FE. "Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study." November 20, 2009. Link to Item
  - Giles, FG, O'Brien, S, Rizzieri, DA, Vey, N, Krug, U, Sekeres, M, Jacobsen, TF, Nilsson, BI, and Staudacher, K. "A phase II study with CP-4055 in patients with second salvage AML." May 20, 2009. Link to Item
  - Rao, AV, Valk, P, Metzeler, KH, Acharya, C, Rizzieri, DA, Delwel, R, Bohlander, SH, Buske, C, Potti, A, and Lowenberg, B. "Age-specific differences in oncogenic pathway deregulation and chemosensitivity in patients with acute myeloid leukemia: Strategies to maximize response to induction chemotherapy." May 20, 2009. Link to Item
  - Smith, G, Rizzieri, DA, Alimena, G, Al-Ali, H-K, Zaritskey, A, Shen, Z, Jootar, S, Hsu, Y, Veronese, ML, and Nicolini, FE. "Expanding nilotinib access in clinical trials (ENACT) study in adult patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in chronic phase (CP), accelerated phase (AP), or blast crisis (BC): updated safety analysis." April 2008. Link to Item
  - Chen, D-F, Prasad, VK, Broadwater, G, Clark, A, Rizzieri, DA, Chao, NJ, and Reinsmoen, NL. "RELEVANCE OF INHIBITORY AND ACTIVATING KIR AND HLA LIGAND ON OUTCOMES IN REDUCED INTENSITY HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTS." 2008. Full Text Link to Item
  - Frankel, AE, Smith, ER, George, TA, Liu, JS, Lee, J, Park, SK, Rizzieri, DA, and Hogge, DE. "Phase I study demonstrates activity and tolerability of diphtheria toxin interleukin-3 fusion protein in patients with AML and MDS." November 16, 2007. Link to Item
  - Weinberg, JB, Jiang, N, Volkheimer, AD, Chen, Y, Bond, KM, Moore, JO, Gockerman, JP, Diehl, LF, de Castro, CM, Rizzieri, DA, Levesque, MC, Mugridge, K, and DeAngelo, J. "Cytotoxicity of the type 4 phosphodiesterase inhibitor CD160130 for freshly isolated human CLL cells in vitro." November 16, 2007. Link to Item
  - Weinberg, JB, Volkheimer, AD, Mihovilovic, M, Jiang, N, Chen, Y, Moore, JO, Gockerman, JP, Diehl, LF, de Castro, CM, Rizzieri, DA, Levesque, MC, DeKroon, R, and Strittmatter, WJ. "Apolipoprotein E (APOE) genotype as a determinant of survival in women with chronic lymphocytic leukemia." November 16, 2007. Link to Item
  - Adams, DJ, Sandvold, ML, Myhren, F, Jacobsen, TF, and Rizzieri, DA. "Antiproliferative activity of ELACYT (TM) (CP-4055) in combination with cloretazine (VNP40101M), idarubicin or gemcitabine in HL-60 human myeloid leukemia cells." November 16, 2006. Link to Item
  - Giles, F, Freedman, SJ, Xiao, A, Borthakur, G, Garcia-Manero, G, Wierda, W, Kornblau, SM, O'Brien, S, Bergstrom, DA, and Rizzieri, DA. "MK-0457, a novel multikinase inhibitor, has activity in refractory AML, including transformed JAK2 positive myeloproliferative disease (MPD), and in Philadelphia-positive ALL." November 16, 2006. Link to Item
  - Giles, F, Freedman, SJ, Xiao, A, Borthakur, G, Garcia-Manero, G, Wierda, W, Kornblau, SM, O'Brien, S, Bergstrom, DA, and Rizzieri, DA. "MK-0457, a novel multikinase inhibitor, has activity in refractory AML, including transformed JAK2 positive myeloproliferative disease (MPD), and in Philadelphia-positive ALL." November 16, 2006. Link to Item
  - Rizzieri, DA, Tse, W, Khan, KD, Advani, A, Donze, J, Karsten, V, Geller, RB, and Gerson, SL. "A phase I study of cloretazine (R) and temozolomide in patients with hematologic malignancies." November 16, 2006. Link to Item
  - Frankel, AE, Weir, MA, Hall, PD, Hogge, DE, and Rizzieri, DA. "Diptheria toxin-interleukin 3 fusion protein therapy of patients with elderly or relapsed/refractory acute myeloid leukemia (AML)." June 20, 2006. Link to Item
  - Prasad, VK, Chen, DF, Reinsmoen, NL, Broadwater, G, Chao, NJ, and Rizzieri, DA. "Impact of donor KIR genotype and recipient hla ligand incompatibility on relapse related mortality and acute graft versus host disease in high-risk patients undergoing haploidentical non-myeloablative peripheral blood stem cell transplants: Differences between lymphoid and myeloid malignancies." February 2006. Full Text Link to Item
  - Byrne, BJ, Antin, JH, Alyea, EP, Choa, NJ, and Rizzieri, DA. "Efficacy of performing a second non-myeloablative allogenic stem cell transplant." November 16, 2005. Link to Item
  - Gasparetto, C, Keogh, GP, Gockerman, JP, Horwitz, M, Moore, JO, DeCastro, C, Diehl, L, Davis, P, Chao, N, and Rizzieri, DA. "A prospective study of bortezomib in combination with melphalan and prednisone for patients with previously untreated multiple myeloma." November 16, 2005. Link to Item
  - Misra, D, Moore, JO, Gockerman, JP, Diehl, L, de Castro, C, Yang, YP, Gasparetto, C, Abernathy, A, Horwitz, M, Long, GD, Chute, J, Peterson, B, Chao, NJ, and Rizzieri, DA. "Phase I study of gemcitabine, fludarabine and mitoxantrone for relapsed or refractory leukemia." November 16, 2005. Link to Item
  - Rizzieri, DA, Feldman, E, Moore, JO, Roboz, GJ, DiPersio, JF, Gabrail, N, Stock, W, Rivera, VM, Albitar, M, Bedrosian, CL, and Giles, F. "A phase 2 clinical trial of AP23573, an mTOR inhibitor, In patients with relapsed or refractory hematologic malignancies." November 16, 2005. Link to Item
  - Rizzieri, DA, Koh, LP, Long, GD, Gasparetto, C, Gong, JZ, Lagoo, AS, Niedzwiecki, D, Sullivan, KM, Chute, J, Horwitz, M, Ashley, M, and Chao, NJ. "Outcome and immune reconstitution following T cell depleted nonmyeloablative allogeneic transplantation using matched donors." November 16, 2005. Link to Item
  - Rizzieri, DA, Koh, LP, Long, GD, Gasparetto, C, Sullivan, KM, Horwitz, M, Chute, J, Gong, JZ, Lagoo, AS, Niedzwiecki, D, Lu, CX, Marshall, D, Dowell, JM, and Chao, NJ. "Partially HLA matched, non-myeloablative allogeneic transplantation." November 16, 2005. Link to Item
  - Wanko, SO, Gockerman, JP, Moore, JO, de Castro, C, Diehl, L, Pronitz, R, Gasparetto, C, Chute, J, Horwitz, M, Morris, A, Ali-Osman, F, Rao, A, Niedzweicki, D, Long, GD, Chao, NJ, and Rizzieri, DA. "Multimodal dose dense therapy for mantle cell lymphoma." November 16, 2005. Link to Item
  - Chen, DF, Prasad, VK, Broadwater, G, Rizzieri, DA, Chao, NJ, and Reinsmoen, NL. "Impact of donor KIR genotype and recipient HLA ligand incompatibility on relapse-related mortality in high-risk patients undergoing haploidentical non-myeloablative peripheral blood stem cell transplants: Differences between lymphoid and myelloid malignanc." November 2005. Link to Item
  - Sebastian, S, Rehder, CW, Lagoo, AS, Gong, JZ, Buckley, PJ, Rizzieri, DA, and Goodman, BK. "An unusual 4-way translocation resulting in a rare BCR-ABL fusion transcript (e13a3) and cytogenetic evolution in chronic myeloid leukemia (CML)." November 2005. Link to Item
  - Grinblatt, DL, Johnson, J, Niedzwicki, D, Rizzieri, DA, Bartlett, N, and Cheson, BD. "Phase II study of thalidomide in escalating doses for follicular (F-NHL) and small lymphocytic lymphoma (Sll): CALGB study 50002." November 16, 2004. Link to Item
  - Koh, LP, Gockerman, JP, Moore, JO, DeCastro, C, Long, GD, Gasparetto, C, Niedzwiecki, D, Edwards, J, Prosnitz, L, Horwitz, M, Chute, J, Morris, A, Lassiter, M, Loftis, J, Davis, P, Chao, NJ, and Rizzieri, DA. "Dose dense, high intensity induction therapy followed by early high dose chemotherapy (HDT) and autologous hematopoietic stem cell transplantation (AHSCT) for mantle cell lymphoma (MCL)." November 16, 2004. Link to Item
  - Misra, D, Frankel, A, Hall, P, Liu, TF, Black, J, Moore, JO, de Castro, C, Gockerman, JP, Gasparetto, C, Horwitz, M, Davis, PH, Chao, NJ, and Rizzieri, DA. "The use of DT388-IL3 fusion protein in patients with refractory acute myeloid leukemia(AML)." November 16, 2004. Link to Item
  - Rao, AV, Rizzieri, DA, Moore, JO, Decastro, C, Abernethy, AP, Jordan, M, Davis, P, Edmonds, E, and Gockerman, JP. "Dose dense, high intensity therapy in newly diagnosed elderly patients with acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg (TM)) and high dose cytarabine (HiDAC)." November 16, 2004. Link to Item
  - Wanko, SO, Gocherman, JP, Moore, JO, Decastro, C, Prosnitz, R, Gasparetto, C, Chute, J, Horowitz, M, Ashley, M, Emily, E, Patty, D, Nelson, CJ, and Rizzieri, DA. "Multimodal dose dense therapy for mantle cell lymphoma." November 16, 2004. Link to Item
  - Gong, JZ, Trembath, DY, Goodman, BK, Quigley, D, Sebastian, S, Rizzieri, DA, Gockerman, JP, Lagoo, AS, and Buckley, PJ. "Detection of genomic losses and gains in myelodysplastic syndrome and acute myeloid leukemia by array comparative genomic hybridization." November 2004. Link to Item
  - Akabani, G, Rizzieri, DA, Zalutsky, MR, Coleman, RE, Metzler, SD, Bowsher, JE, Toaso, B, Lagoo, A, Moore, JO, Gockerman, JP, DeCastro, C, Gasparetto, C, Chao, NJ, and Bigner, DD. "Phase I trial study of [131]I-labeled chimeric 81C6 mAb for the treatment of patients with non-Hodgkin's lymphoma." August 2004. Link to Item
  - Gasparetto, C, Chao, NJ, Horwitz, ME, Moore, JO, DeCastro, C, Gockerman, J, Sullivan, K, Rooney, B, Houser, L, Anderson, E, Hale, G, Toaso, B, and Rizzieri, DA. "Pharmacokinetics of subcutaneous alemtuzumab in a patient with myeloma." November 16, 2003. Link to Item
  - Goggins, TF, Rizzieri, DA, Prosnitz, R, Gasparetto, C, Long, G, Horwitz, ME, Sullivan, K, Morris, A, Thompson, M, Lassiter, M, Rowe, K, and Chao, NJ. "One day preparative regimen for allogeneic non-myeloablative stem cell transplantation (NMSCT) using 3-5/6 HLA matched related donors." November 16, 2003. Link to Item
  - Rizzieri, DA, Akabani, G, Zalutsky, M, Coleman, RE, Toaso, B, Anderson, E, Lagoo, A, Clayton, S, Niedzwiecki, D, Moore, JO, Gockerman, JP, DeCastro, C, Chao, NJ, Gasparetto, C, and Bigner, DD. "Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using I-131 labeled chimeric anti-tenascin therapy for lymphoma." November 16, 2003. Link to Item
  - Rizzieri, DA, Koh, LP, Long, GD, Gasparetto, C, Vredenburgh, JJ, Buckley, PJ, Gong, G, Lagoo, A, Davis, P, Lassiter, M, Rooney, B, Niedzwiecki, D, Waters-Pick, B, Burleson, J, Thompson, M, Johns, A, Folz, RJ, Horwtiz, ME, Sullivan, K, Morris, A, and Chao, NJ. "Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy using HLA mis-matched (3-5/6) related hematopoietic stem cells." November 16, 2003. Link to Item
  - Rizzieri, DA, Koh, LP, Long, GD, Lagoo, AS, Gasparatto, C, Vredenburgh, JJ, Buckley, PJ, Gong, G, Loftis, J, Rowe, K, Rooney, B, Niedzweicki, D, Waters-Pick, B, Eren, P, Vujevich, D, Catlin, C, Folz, RJ, Sullivan, K, Horwitz, ME, Morris, A, and Chao, NJ. "Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy from HLA matched siblings." November 16, 2003. Link to Item
  - Rizzieri, DA, Sand, GJ, McGaughey, D, Moore, J, DeCastro, C, Chao, N, Vredenburgh, J, Gasparetto, C, Anderson, L, Foster, T, Niedzwiecki, D, and Gockerman, J. "Low-dose weekly paclitaxel for relapsed or refractory aggressive non-Hodgkins lymphoma." November 16, 2003. Link to Item
  - Sand, GJ, Moore, JO, DeCastro, C, Gockerman, JP, Peterson, B, Buckley, PJ, Toaso, B, Adams, D, and Rizzieri, DA. "Phase one evaluation of gemcitabine, fludarabine, and mitoxantrone for relapsed or refractory leukemia." November 16, 2003. Link to Item
  - Talbot, JT, Ibom, VK, Barrier, R, Niedzwieki, D, Castro, CM, Moore, JO, Buckley, PJ, Laney, R, Stevenson, D, Brumbaugh, H, Rizzieri, DA, and Gockerman, JP. "Dose-intense cyclophosphamide and etoposide for patients with refractory or high risk non-Hogdkin's lymphoma." November 16, 2003. Link to Item
  - de Castro, CM, Uronis, H, Moore, JO, Gockerman, JP, Rizzieri, DA, and Chao, NJ. "Successful treatment of pure red cell aplasia (PRCA) with alemtuzumab (CAMPATH-1H)." November 16, 2003. Link to Item
  - Snyder, MJ, Stenzel, TT, Lagoo, AS, Rizzieri, DA, Chao, N, Buckley, PJ, and Gong, JZ. "Post-transplant lymphoproliferative disorder following non-myeloablative allogeneic stem cell transplantation." January 2003. Link to Item
  - Snyder, MJ, Stenzel, TT, Lagoo, AS, Rizzieri, DA, Chao, N, Buckley, PJ, and Gong, JZ. "Post-transplant lymphoproliferative disorder following non-myeloablative allogeneic stem cell transplantation." January 2003. Link to Item
  - Foran, J, Wetzler, M, Karitarjian, HM, Faderl, S, Abramson, N, Rizzieri, DA, Craig, A, Weiss, J, and Douer, D. "A phase II, open-label study of CLOPAREX(TM) in adult patients with refractory or relapsed acute myelogenous leukemia." November 16, 2002. Link to Item
  - Gandy, KL, Chao, NJ, Long, GD, Sartain, V, Seigler, HF, and Rizzieri, DA. "Donor-specific tolerance after hematopoietic reconstitution with Campath-1H treated mobilized peripheral blood cells in a sublethal preconditioning regimen." November 16, 2002. Link to Item
  - Isola, LM, Chao, JN, Weinberg, S, Fruchtman, SM, Atweh, G, McCune, S, Telen, MJ, DeCastro, LM, Long, GD, Vredenburgh, JJ, Gasparetto, C, Liesveld, J, Rowley, S, and Rizzieri, DA. "Donor chimerism after T-Cell depleted (TCD)-Non-Myeloablative allogeneic SCT (NST) in hemoglobinopathies." November 16, 2002. Link to Item
  - Johnston, LJ, Shizuru, JS, Stockerl-Goldstein, KE, Stuart, MJ, Gasparetto, C, Long, GD, Rizzieri, DA, Vredenburgh, JJ, Blume, KG, Negrin, RS, and Chao, NJ. "GLAT (Copaxone) for treatment of steroid-refractory acute graft versus host disease." November 16, 2002. Link to Item
  - Koh, LP, Rizzieri, DA, Long, GD, Vredenburgh, JJ, Gaparetto, C, Morris, A, Water-Picks, B, Stenzel, T, Lagoo, A, Gong, J, Buckley, P, and Chao, NJ. "Campath-1H, T cell depleted nonmyeloablative peripheral blood stem cell transplantation from 3-6/6 HLA matched family members." November 16, 2002. Link to Item
  - Lonial, S, Rizzieri, DA, Koh, LP, Jones, M, Langston, AA, Redei, I, Long, GD, Gasparetto, C, Vredenburgh, JJ, Waller, EK, and Chao, N. "Three methods of T-cell depletion of HPCT products: Analysis of CD34+ cell and lymphocyte purity and recovery." November 16, 2002. Link to Item
  - Rai, KR, Keating, MJ, Coutre, S, Rizzieri, DA, and Grp, CS. "Patients with refractory B-CLL and T-PLL treated with alemtuzumab (Campath (R)) on a compassionate basis. A report on efficacy and safety of CAM 511 trial." November 16, 2002. Link to Item
  - Morse, MA, Rizzieri, D, Hobeika, AC, Chao, N, and Lyerly, HK. "Dendritic cell (DC) reconstitution after nonmyeloablative allogeneic stem cell transplants." 2000.
- Journal Articles
  - Batlevi, CL, Crump, M, Andreadis, C, Rizzieri, D, Assouline, SE, Fox, S, van der Jagt, RHC, Copeland, A, Potvin, D, Chao, R, and Younes, A. "A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma." British Journal of Haematology 178, no. 3 (August 2017): 434-441. Full Text
  - Boss, MK, Dewhirst, MW, Sampaio, RS, Bennett, A, Tovmasyan, A, Berman, KG, Beaven, AW, Rizzieri, DA, Batinic-Haberle, I, Hauck, ML, and Spasojevic, I. "Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy." Cancer chemotherapy and pharmacology 80, no. 2 (August 2017): 421-431. Full Text
  - Kantarjian, HM, Roboz, GJ, Kropf, PL, Yee, KWL, O'Connell, CL, Tibes, R, Walsh, KJ, Podoltsev, NA, Griffiths, EA, Jabbour, E, Garcia-Manero, G, Rizzieri, D, Stock, W, Savona, MR, Rosenblat, TL, Berdeja, JG, Ravandi, F, Rock, EP, Hao, Y, Azab, M, and Issa, J-PJ. "Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial." The Lancet Oncology (August 2017). Full Text
  - Anand, S, Thomas, S, Hyslop, T, Adcock, J, Corbet, K, Gasparetto, C, Lopez, R, Long, GD, Morris, AK, Rizzieri, DA, Sullivan, KM, Sung, AD, Sarantopoulos, S, Chao, NJ, and Horwitz, ME. "Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 23, no. 7 (July 2017): 1151-1157. Full Text
  - Michelis, FV, Gupta, V, Zhang, M-J, Wang, H-L, Aljurf, M, Bacher, U, Beitinjaneh, A, Chen, Y-B, DeFilipp, Z, Gale, RP, Kebriaei, P, Kharfan-Dabaja, M, Lazarus, HM, Nishihori, T, Olsson, RF, Oran, B, Rashidi, A, Rizzieri, DA, Tallman, MS, de Lima, M, Khoury, HJ, Sandmaier, BM, Weisdorf, D, and Saber, W et al. "Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis." Cancer 123, no. 11 (June 2017): 2035-2042. Full Text
  - El-Jawahri, A, Chen, Y-B, Brazauskas, R, He, N, Lee, SJ, Knight, JM, Majhail, N, Buchbinder, D, Schears, RM, Wirk, BM, Wood, WA, Ahmed, I, Aljurf, M, Szer, J, Beattie, SM, Battiwalla, M, Dandoy, C, Diaz, M-A, D'Souza, A, Freytes, CO, Gajewski, J, Gergis, U, Hashmi, SK, Jakubowski, A, Kamble, RT, Kindwall-Keller, T, Lazarus, HM, Malone, AK, Marks, DI, Meehan, K, Savani, BN, Olsson, RF, Rizzieri, D, Steinberg, A, Speckhart, D, Szwajcer, D, Schoemans, H, Seo, S, Ustun, C, Atsuta, Y, and Dalal, J et al. "Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation." Cancer 123, no. 10 (May 2017): 1828-1838. Full Text
  - Liu, HD, Ahn, KW, Hu, Z-H, Hamadani, M, Nishihori, T, Wirk, B, Beitinjaneh, A, Rizzieri, D, Grunwald, MR, Sabloff, M, Olsson, RF, Bajel, A, Bredeson, C, Daly, A, Inamoto, Y, Majhail, N, Saad, A, Gupta, V, Gerds, A, Malone, A, Tallman, M, Reshef, R, Marks, DI, Copelan, E, Gergis, U, Savoie, ML, Ustun, C, Litzow, MR, Cahn, J-Y, Kindwall-Keller, T, Akpek, G, Savani, BN, Aljurf, M, Rowe, JM, Wiernik, PH, Hsu, JW, Cortes, J, Kalaycio, M, Maziarz, R, Sobecks, R, Popat, U, Alyea, E, and Saber, W. "Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia." Biology of Blood and Marrow Transplantation 23, no. 5 (May 2017): 767-775. Full Text
  - Sivaraj, D, Green, MM, Li, Z, Sung, AD, Sarantopoulos, S, Kang, Y, Long, GD, Horwitz, ME, Lopez, RD, Sullivan, KM, Rizzieri, DA, Chao, NJ, and Gasparetto, C. "Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 23, no. 2 (February 2017): 262-268. Full Text
  - Huang, L-W, Bacon, W, Cirrincione, C, Peterson, B, Long, G, Rizzieri, D, Sullivan, KM, Corbet, K, Horwitz, M, Chao, N, Gasparetto, C, and Tuchman, SA. "Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma." Hematological oncology (January 19, 2017). Full Text
  - Sullivan, JM, and Rizzieri, DA. "Treatment of blastic plasmacytoid dendritic cell neoplasm." Hematology. American Society of Hematology. Education Program 2016, no. 1 (December 2016): 16-23. (Review) Full Text
  - Bajaj, J, Konuma, T, Lytle, NK, Kwon, HY, Ablack, JN, Cantor, JM, Rizzieri, D, Chuah, C, Oehler, VG, Broome, EH, Ball, ED, van der Horst, EH, Ginsberg, MH, and Reya, T. "CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia." Cancer cell 30, no. 5 (November 2016): 792-805. Full Text
  - Rizzieri, D. "Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?." Critical reviews in oncology/hematology 105 (September 2016): 5-17. (Review) Full Text
  - Rizzieri, DA, Cooley, S, Odenike, O, Moonan, L, Chow, KH, Jackson, K, Wang, X, Brail, L, and Borthakur, G. "An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia." Leukemia & lymphoma 57, no. 8 (August 2016): 1800-1806. Full Text
  - Shaffer, BC, Ahn, KW, Hu, Z-H, Nishihori, T, Malone, AK, Valcárcel, D, Grunwald, MR, Bacher, U, Hamilton, B, Kharfan-Dabaja, MA, Saad, A, Cutler, C, Warlick, E, Reshef, R, Wirk, BM, Sabloff, M, Fasan, O, Gerds, A, Marks, D, Olsson, R, Wood, WA, Costa, LJ, Miller, AM, Cortes, J, Daly, A, Kindwall-Keller, TL, Kamble, R, Rizzieri, DA, Cahn, J-Y, Gale, RP, William, B, Litzow, M, Wiernik, PH, Liesveld, J, Savani, BN, Vij, R, Ustun, C, Copelan, E, Popat, U, Kalaycio, M, Maziarz, R, and Alyea, E et al. "Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, no. 16 (June 2016): 1864-1871. Full Text
  - Zahid, MF, and Rizzieri, DA. "Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders." Advances in hematology 2016 (January 2016): 1423493-. (Review) Full Text
  - Urbano-Ispizua, A, Pavletic, SZ, Flowers, ME, Klein, JP, Zhang, M-J, Carreras, J, Montoto, S, Perales, M-A, Aljurf, MD, Akpek, G, Bredeson, CN, Costa, LJ, Dandoy, C, Freytes, CO, Fung, HC, Gale, RP, Gibson, J, Hamadani, M, Hayashi, RJ, Inamoto, Y, Inwards, DJ, Lazarus, HM, Maloney, DG, Martino, R, Munker, R, Nishihori, T, Olsson, RF, Rizzieri, DA, Reshef, R, Saad, A, Savani, BN, Schouten, HC, Smith, SM, Socié, G, Wirk, B, Yu, LC, and Saber, W. "The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 21, no. 10 (October 2015): 1746-1753. Full Text
  - Griffin, PT, Komrokji, RS, De Castro, CM, Rizzieri, DA, Melchert, M, List, AF, and Lancet, JE. "A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy." American journal of hematology 90, no. 9 (September 2015): 796-799. Full Text
  - Issa, J-PJ, Roboz, G, Rizzieri, D, Jabbour, E, Stock, W, O'Connell, C, Yee, K, Tibes, R, Griffiths, EA, Walsh, K, Daver, N, Chung, W, Naim, S, Taverna, P, Oganesian, A, Hao, Y, Lowder, JN, Azab, M, and Kantarjian, H. "Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study." The Lancet. Oncology 16, no. 9 (September 2015): 1099-1110. Full Text
  - Kwon, HY, Bajaj, J, Ito, T, Blevins, A, Konuma, T, Weeks, J, Lytle, NK, Koechlein, CS, Rizzieri, D, Chuah, C, Oehler, VG, Sasik, R, Hardiman, G, and Reya, T. "Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia." Cell stem cell 17, no. 2 (August 2015): 152-164. Full Text
  - Davis, C, and Rizzieri, D. "Immunotherapeutic Applications of NK Cells." Pharmaceuticals 8, no. 2 (June 2015): 250-256. Full Text
  - Tuchman, SA, Bacon, WA, Huang, L-W, Long, G, Rizzieri, D, Horwitz, M, Chute, JP, Sullivan, K, Morris Engemann, A, Yopp, A, Li, Z, Corbet, K, Chao, N, and Gasparetto, C. "Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma." Journal of clinical apheresis 30, no. 3 (June 2015): 176-182. Full Text
  - Stone, RM, Mazzola, E, Neuberg, D, Allen, SL, Pigneux, A, Stuart, RK, Wetzler, M, Rizzieri, D, Erba, HP, Damon, L, Jang, J-H, Tallman, MS, Warzocha, K, Masszi, T, Sekeres, MA, Egyed, M, Horst, H-A, Selleslag, D, Solomon, SR, Venugopal, P, Lundberg, AS, and Powell, B. "Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33, no. 11 (April 2015): 1252-1257. Full Text
  - Bachanova, V, Burns, LJ, Wang, T, Carreras, J, Gale, RP, Wiernik, PH, Ballen, KK, Wirk, B, Munker, R, Rizzieri, DA, Chen, YB, Gibson, J, Akpek, G, Costa, LJ, Kamble, RT, Aljurf, MD, Hsu, JW, Cairo, MS, Schouten, HC, Bacher, U, Savani, BN, Wingard, JR, Lazarus, HM, Laport, GG, Montoto, S, Maloney, DG, Smith, SM, Brunstein, C, and Saber, W. "Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor." Bone Marrow Transplantation 50, no. 2 (February 7, 2015): 197-203. Full Text
  - Bachanova, V, Burns, LJ, Wang, T, Carreras, J, Gale, RP, Wiernik, PH, Ballen, KK, Wirk, B, Munker, R, Rizzieri, DA, Chen, Y-B, Gibson, J, Akpek, G, Costa, LJ, Kamble, RT, Aljurf, MD, Hsu, JW, Cairo, MS, Schouten, HC, Bacher, U, Savani, BN, Wingard, JR, Lazarus, HM, Laport, GG, Montoto, S, Maloney, DG, Smith, SM, Brunstein, C, and Saber, W. "Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor." Bone marrow transplantation 50, no. 2 (February 2015): 197-203. Full Text
  - Chen, W, Rizzieri, D, and Drago, S. "Safety of growth factor administration for leukapheresis in those with WBC counts greater than 60,000/µl." Journal of Clinical Apheresis 30, no. 1 (February 2015): 28-31. Full Text
  - Chen, W, Rizzieri, D, and Drago, S. "Safety of growth factor administration for leukapheresis in those with WBC counts greater than 60,000/µl." Journal of clinical apheresis 30, no. 1 (February 2015): 28-31. Full Text
  - Tuchman, SA, Bacon, WA, Huang, LW, Long, G, Rizzieri, D, Horwitz, M, Chute, JP, Sullivan, K, Engemann, AM, Yopp, A, Li, Z, Corbet, K, Chao, N, and Gasparetto, C. "Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma." Journal of Clinical Apheresis 30, no. 3 (January 1, 2015): 176-182. Full Text
  - Stein, EM, Garcia-Manero, G, Rizzieri, DA, Savona, M, Tibes, R, Altman, JK, Jongen-Lavrencic, M, Doehner, H, Armstrong, S, Pollock, RM, Waters, NJ, Legler, M, Thomson, B, Daigle, S, McDonald, A, Campbell, C, Olhava, E, Hedrick, EE, Lowenberg, B, Copeland, RA, and Tallman, MS. "The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia." BLOOD 124, no. 21 (December 6, 2014). Link to Item
  - Rein, LAM, and Rizzieri, DA. "Clinical potential of elacytarabine in patients with acute myeloid leukemia." Therapeutic advances in hematology 5, no. 6 (December 2014): 211-220. (Review) Full Text
  - Hamadani, M, Hari, PN, Zhang, Y, Carreras, J, Akpek, G, Aljurf, MD, Ayala, E, Bachanova, V, Chen, AI, Chen, Y-B, Costa, LJ, Fenske, TS, Freytes, CO, Ganguly, S, Hertzberg, MS, Holmberg, LA, Inwards, DJ, Kamble, RT, Kanfer, EJ, Lazarus, HM, Marks, DI, Nishihori, T, Olsson, R, Reddy, NM, Rizzieri, DA, Savani, BN, Solh, M, Vose, JM, Wirk, B, Maloney, DG, Smith, SM, Montoto, S, Saber, W, Alpdogan, O, Cashen, A, Dandoy, C, Finke, R, Gale, R, Gibson, J, Hsu, JW, Janakiraman, N, Laughlin, MJ, and Lill, M et al. "Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20, no. 11 (November 2014): 1729-1736. Full Text
  - Hamadani, M, Hari, PN, Zhang, Y, Carreras, J, Akpek, G, Aljurf, MD, Ayala, E, Bachanova, V, Chen, AI, Chen, YB, Costa, LJ, Fenske, TS, Freytes, CO, Ganguly, S, Hertzberg, MS, Holmberg, LA, Inwards, DJ, Kamble, RT, Kanfer, EJ, Lazarus, HM, Marks, DI, Nishihori, T, Olsson, R, Reddy, NM, Rizzieri, DA, Savani, BN, Solh, M, Vose, JM, Wirk, B, Maloney, DG, Smith, SM, Montoto, S, and Saber, W. "Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation." Biology of Blood and Marrow Transplantation 20, no. 11 (November 1, 2014): 1729-1736. Full Text
  - Liu, T, Kishton, RJ, Macintyre, AN, Gerriets, VA, Xiang, H, Liu, X, Abel, ED, Rizzieri, D, Locasale, JW, and Rathmell, JC. "Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis." Cell death & disease 5 (October 16, 2014): e1470-. Full Text
  - Rizzieri, D, Vey, N, Thomas, X, Huguet-Rigal, F, Schlenk, RF, Krauter, J, Kindler, T, Gjertsen, BT, Blau, IW, Jacobsen, TF, Johansen, M, Bergeland, T, Gianella-Borradori, A, and Krug, U. "A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course." Leukemia & lymphoma 55, no. 9 (September 2014): 2114-2119. Full Text
  - Horwitz, ME, Chao, NJ, Rizzieri, DA, Long, GD, Sullivan, KM, Gasparetto, C, Chute, JP, Morris, A, McDonald, C, Waters-Pick, B, Stiff, P, Wease, S, Peled, A, Snyder, D, Cohen, EG, Shoham, H, Landau, E, Friend, E, Peleg, I, Aschengrau, D, Yackoubov, D, Kurtzberg, J, and Peled, T. "Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment." The Journal of clinical investigation 124, no. 7 (July 2014): 3121-3128. Full Text
  - Wirk, B, Fenske, TS, Hamadani, M, Zhang, M-J, Hu, Z-H, Akpek, G, Aljurf, MD, Armand, P, Ayala, E, Bachanova, V, Bolwell, B, Cairo, MS, Cashen, A, Chen, Y-B, Costa, LJ, Farhan, S, Freytes, CO, Gajewski, JL, Gibson, J, Hale, GA, Holmberg, LA, Hsu, JW, Inwards, DJ, Kamble, RT, Maharaj, D, Maziarz, RT, Munker, R, Nath, R, Reddy, NM, Reeder, CB, Rizzieri, DA, Sauter, CS, Savani, BN, Schouten, HC, Sureda, A, Vose, JM, Waller, EK, Wiernik, PH, Gale, RP, Burns, LJ, and Saber, W. "Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20, no. 7 (July 2014): 951-959. Full Text
  - Rizzieri, DA, Johnson, JL, Byrd, JC, Lozanski, G, Blum, KA, Powell, BL, Shea, TC, Nattam, S, Hoke, E, Cheson, BD, Larson, RA, and Alliance for Clinical Trials In Oncology (ACTION), . "Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002." British journal of haematology 165, no. 1 (April 2014): 102-111. Full Text
  - Allen, JL, Tata, PV, Fore, MS, Wooten, J, Rudra, S, Deal, AM, Sharf, A, Hoffert, T, Roehrs, PA, Shea, TC, Serody, JS, Richards, KL, Jagasia, M, Lee, SJ, Rizzieri, D, Horwitz, ME, Chao, NJ, and Sarantopoulos, S. "Increased BCR responsiveness in B cells from patients with chronic GVHD." Blood 123, no. 13 (March 2014): 2108-2115. Full Text
  - Fenske, TS, Zhang, M-J, Carreras, J, Ayala, E, Burns, LJ, Cashen, A, Costa, LJ, Freytes, CO, Gale, RP, Hamadani, M, Holmberg, LA, Inwards, DJ, Lazarus, HM, Maziarz, RT, Munker, R, Perales, M-A, Rizzieri, DA, Schouten, HC, Smith, SM, Waller, EK, Wirk, BM, Laport, GG, Maloney, DG, Montoto, S, and Hari, PN. "Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality." J Clin Oncol 32, no. 4 (February 1, 2014): 273-281. Full Text Link to Item
  - Kanda, J, Long, GD, Gasparetto, C, Horwitz, ME, Sullivan, KM, Chute, JP, Morris, A, Shafique, M, Li, Z, Chao, NJ, and Rizzieri, DA. "Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies." Biol Blood Marrow Transplant 20, no. 2 (February 2014): 257-263. Full Text Link to Item
  - Rizzieri, D. "Is timing everything?." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20, no. 2 (February 2014): 145-146. Full Text
  - Liu, T, Kishton, RJ, Macintyre, AN, Gerriets, VA, Xiang, H, Liu, X, Abel, ED, Rizzieri, D, Locasale, JW, and Rathmell, JC. "Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis." Cell death & disease 5 (2014): e1516-. Full Text
  - Rizzieri, DA, Johnson, JL, Byrd, JC, Lozanski, G, Blum, KA, Powell, BL, Shea, TC, Nattam, S, Hoke, E, Cheson, BD, and Larson, RA. "Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10 002." British Journal of Haematology 165, no. 1 (January 1, 2014): 102-111. Full Text
  - Wirk, B, Fenske, TS, Hamadani, M, Zhang, MJ, Hu, ZH, Akpek, G, Aljurf, MD, Armand, P, Ayala, E, Bachanova, V, Bolwell, B, Cairo, MS, Cashen, A, Chen, YB, Costa, LJ, Farhan, S, Freytes, CO, Gajewski, JL, Gibson, J, Hale, GA, Holmberg, LA, Hsu, JW, Inwards, DJ, Kamble, RT, Maharaj, D, Maziarz, RT, Munker, R, Nath, R, Reddy, NM, Reeder, CB, Rizzieri, DA, Sauter, CS, Savani, BN, Schouten, HC, Sureda, A, Vose, JM, Waller, EK, Wiernik, PH, Gale, RP, Burns, LJ, and Saber, W. "Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma." Biology of Blood and Marrow Transplantation 20, no. 7 (January 1, 2014): 951-959. Full Text
  - Zimdahl, B, Ito, T, Blevins, A, Bajaj, J, Konuma, T, Weeks, J, Koechlein, CS, Kwon, HY, Arami, O, Rizzieri, D, Broome, HE, Chuah, C, Oehler, VG, Sasik, R, Hardiman, G, and Reya, T. "Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia." Nature Genetics 46, no. 3 (January 1, 2014): 245-252. Full Text
  - Brander, D, Rizzieri, D, Gockerman, J, Diehl, L, Shea, TC, Decastro, C, Moore, JO, and Beaven, A. "Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma." Leuk Lymphoma 54, no. 12 (December 2013): 2627-2630. Full Text Link to Item
  - Armand, P, Nagler, A, Weller, EA, Devine, SM, Avigan, DE, Chen, Y-B, Kaminski, MS, Holland, HK, Winter, JN, Mason, JR, Fay, JW, Rizzieri, DA, Hosing, CM, Ball, ED, Uberti, JP, Lazarus, HM, Mapara, MY, Gregory, SA, Timmerman, JM, Andorsky, D, Or, R, Waller, EK, Rotem-Yehudar, R, and Gordon, LI. "Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial." J Clin Oncol 31, no. 33 (November 20, 2013): 4199-4206. Full Text Link to Item
  - Lee, SJ, Storer, B, Wang, H, Lazarus, HM, Waller, EK, Isola, LM, Klumpp, TR, Umejiego, JBC, Savani, BN, Loren, AW, Cairo, MS, Camitta, BM, Cutler, CS, George, B, Jean Khoury, H, Marks, DI, Rizzieri, DA, Copelan, EA, Gupta, V, Liesveld, JL, Litzow, MR, Miller, AM, Schouten, HC, Gale, RP, Cahn, J-Y, and Weisdorf, DJ. "Providing personalized prognostic information for adult leukemia survivors." Biol Blood Marrow Transplant 19, no. 11 (November 2013): 1600-1607. Full Text Link to Item
  - Maziarz, RT, Wang, Z, Zhang, M-J, Bolwell, BJ, Chen, AI, Fenske, TS, Freytes, CO, Gale, RP, Gibson, J, Hayes-Lattin, BM, Holmberg, L, Inwards, DJ, Isola, LM, Khoury, HJ, Lewis, VA, Maharaj, D, Munker, R, Phillips, GL, Rizzieri, DA, Rowlings, PA, Saber, W, Satwani, P, Waller, EK, Maloney, DG, Montoto, S, Laport, GG, Vose, JM, Lazarus, HM, and Hari, PN. "Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement." Br J Haematol 162, no. 5 (September 2013): 648-656. Full Text Link to Item
  - Kanda, J, Kaynar, L, Kanda, Y, Prasad, VK, Parikh, SH, Lan, L, Shen, T, Rizzieri, DA, Long, GD, Sullivan, KM, Gasparetto, C, Chute, JP, Morris, A, Winkel, S, McPherson, J, Kurtzberg, J, Chao, NJ, and Horwitz, ME. "Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment." Bone Marrow Transplant 48, no. 7 (July 2013): 926-931. Full Text Link to Item
  - Lim, S, Saw, TY, Zhang, M, Janes, MR, Nacro, K, Hill, J, Lim, AQ, Chang, C-T, Fruman, DA, Rizzieri, DA, Tan, SY, Fan, H, Chuah, CTH, and Ong, ST. "Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 110, no. 25 (June 18, 2013): E2298-E2307. Full Text Link to Item
  - Hamadani, M, Saber, W, Ahn, KW, Carreras, J, Cairo, MS, Fenske, TS, Gale, RP, Gibson, J, Hale, GA, Hari, PN, Hsu, JW, Inwards, DJ, Kamble, RT, Klein, A, Maharaj, D, Marks, DI, Rizzieri, DA, Savani, BN, Schouten, HC, Waller, EK, Wirk, B, Laport, GG, Montoto, S, Maloney, DG, and Lazarus, HM. "Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma." Biol Blood Marrow Transplant 19, no. 5 (May 2013): 746-753. Full Text Link to Item
  - O'Brien, JA, and Rizzieri, DA. "Leukemic stem cells: a review." Cancer Invest 31, no. 4 (May 2013): 215-220. (Review) Full Text Link to Item
  - Hamadani, M, Saber, W, Ahn, KW, Carreras, J, Cairo, MS, Fenske, TS, Gale, RP, Gibson, J, Hale, GA, Hari, PN, Hsu, JW, Inwards, DJ, Kamble, RT, Klein, A, Maharaj, D, Marks, DI, Rizzieri, DA, Savani, BN, Schouten, HC, Waller, EK, Wirk, B, and Lazarus, HM. "Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research." Biol Blood Marrow Transplant 19, no. 4 (April 2013): 625-631. Full Text Link to Item
  - Held, LA, Rizzieri, D, Long, GD, Gockerman, JP, Diehl, LF, de Castro, CM, Moore, JO, Horwitz, ME, Chao, NJ, and Gasparetto, C. "A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma." Cancer Invest 31, no. 3 (March 2013): 172-176. Full Text Link to Item
  - Kurokawa, M, Ito, T, Yang, C-S, Zhao, C, Macintyre, AN, Rizzieri, DA, Rathmell, JC, Deininger, MW, Reya, T, and Kornbluth, S. "Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells." Proc Natl Acad Sci U S A 110, no. 6 (February 5, 2013): 2300-2305. Full Text Open Access Copy Link to Item
  - Maramattom, LV, Hari, PN, Burns, LJ, Carreras, J, Arcese, W, Cairo, MS, Costa, LJ, Fenske, TS, Lill, M, Freytes, CO, Gale, RP, Gross, TG, Hale, GA, Hamadani, M, Holmberg, LA, Hsu, JW, Inwards, DJ, Lazarus, HM, Marks, DI, Maloney, DG, Maziarz, RT, Montoto, S, Rizzieri, DA, Wirk, B, and Gajewski, JL. "Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research." Biol Blood Marrow Transplant 19, no. 2 (February 2013): 173-179. Full Text Link to Item
  - Rein, LA, Sung, AD, and Rizzieri, DA. "New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation." International journal of hematologic oncology 2, no. 1 (February 2013). Full Text
  - Zhang, J, Grubor, V, Love, CL, Banerjee, A, Richards, KL, Mieczkowski, PA, Dunphy, C, Choi, W, Au, WY, Srivastava, G, Lugar, PL, Rizzieri, DA, Lagoo, AS, Bernal-Mizrachi, L, Mann, KP, Flowers, C, Naresh, K, Evens, A, Gordon, LI, Czader, M, Gill, JI, Hsi, ED, Liu, Q, Fan, A, Walsh, K, Jima, D, Smith, LL, Johnson, AJ, Byrd, JC, Luftig, MA, Ni, T, Zhu, J, Chadburn, A, Levy, S, Dunson, D, and Dave, SS. "Genetic heterogeneity of diffuse large B-cell lymphoma." Proc Natl Acad Sci U S A 110, no. 4 (January 22, 2013): 1398-1403. Full Text Link to Item
  - Cortes, J, Feldman, E, Yee, K, Rizzieri, D, Advani, AS, Charman, A, Spruyt, R, Toal, M, and Kantarjian, H. "Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study." The Lancet Oncology (2013). Full Text
  - Cortes, J, Feldman, E, Yee, K, Rizzieri, D, Advani, AS, Charman, A, Spruyt, R, Toal, M, and Kantarjian, H. "Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): A randomised open-label phase 2 study." The Lancet Oncology 14, no. 4 (2013): 354-362. Full Text
  - Giles, FJ, Swords, RT, Nagler, A, Hochhaus, A, Ottmann, OG, Rizzieri, DA, Talpaz, M, Clark, J, Watson, P, Xiao, A, Zhao, B, Bergstrom, D, Coutre, PDL, Freedman, SJ, and Cortes, JE. "MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia." Leukemia 27, no. 1 (2013): 113-117. Full Text
  - Giles, FJ, Swords, RT, Nagler, A, Hochhaus, A, Ottmann, OG, Rizzieri, DA, Talpaz, M, Clark, J, Watson, P, Xiao, A, Zhao, B, Bergstrom, D, Le Coutre, PD, Freedman, SJ, and Cortes, JE. "MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia." Leukemia 27, no. 1 (January 2013): 113-117. Full Text Link to Item
  - Kanda, J, Kaynar, L, Kanda, Y, Prasad, VK, Parikh, SH, Lan, L, Shen, T, Rizzieri, DA, Long, GD, Sullivan, KM, Gasparetto, C, Chute, JP, Morris, A, Winkel, S, McPherson, J, Kurtzberg, J, Chao, NJ, and Horwitz, ME. "Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: Risk factors and response to treatment." Bone Marrow Transplantation 48, no. 7 (2013): 926-931. Full Text
  - Maziarz, RT, Wang, Z, Zhang, M-J, Bolwell, BJ, Chen, AI, Fenske, TS, Freytes, CO, Gale, RP, Gibson, J, Hayes-Lattin, BM, Holmberg, L, Inwards, DJ, Isola, LM, Khoury, HJ, Lewis, VA, Maharaj, D, Munker, R, Phillips, GL, Rizzieri, DA, Rowlings, PA, Saber, W, Satwani, P, Waller, EK, Maloney, DG, Montoto, S, Laport, GG, Vose, JM, Lazarus, HM, and Hari, PN. "Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement." British Journal of Haematology 162, no. 5 (2013): 648-656. Full Text
  - Morris, TA, DeCastro, CM, Diehl, LF, Gockerman, JP, Lagoo, AS, Li, Z, Moore, JO, Rizzieri, DA, and Rao, AV. "Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia." Leuk Res 37, no. 1 (January 2013): 28-31. Full Text Link to Item
  - Rizzieri, DA. "MDS: unraveling the mystery." Blood 120, no. 25 (December 13, 2012): 4906-4908. Full Text Link to Item
  - Love, C, Sun, Z, Jima, D, Li, G, Zhang, J, Miles, R, Richards, KL, Dunphy, CH, Choi, WWL, Srivastava, G, Lugar, PL, Rizzieri, DA, Lagoo, AS, Bernal-Mizrachi, L, Mann, KP, Flowers, CR, Naresh, KN, Evens, AM, Chadburn, A, Gordon, LI, Czader, MB, Gill, JI, Hsi, ED, Greenough, A, Moffitt, AB, McKinney, M, Banerjee, A, Grubor, V, Levy, S, Dunson, DB, and Dave, SS. "The genetic landscape of mutations in Burkitt lymphoma." Nat Genet 44, no. 12 (December 2012): 1321-1325. Full Text Link to Item
  - Kanda, J, Chiou, L-W, Szabolcs, P, Sempowski, GD, Rizzieri, DA, Long, GD, Sullivan, KM, Gasparetto, C, Chute, JP, Morris, A, McPherson, J, Hale, J, Livingston, JA, Broadwater, G, Niedzwiecki, D, Chao, NJ, and Horwitz, ME. "Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation." Biol Blood Marrow Transplant 18, no. 11 (November 2012): 1664-1676.e1. Full Text Link to Item
  - Spasojevic, I, da Costa, LRS, Horwitz, ME, Long, GD, Sullivan, KM, Chute, JP, Gasparetto, C, Morris, A, Chao, NJ, and Rizzieri, DA. "Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry." Cancer Invest 30, no. 9 (November 2012): 679-682. Full Text Link to Item
  - O'Brien, S, Rizzieri, DA, Vey, N, Ravandi, F, Krug, UO, Sekeres, MA, Dennis, M, Venditti, A, Berry, DA, Jacobsen, TF, Staudacher, K, Bergeland, T, and Giles, FJ. "Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia." Br J Haematol 158, no. 5 (September 2012): 581-588. Full Text Link to Item
  - Horwitz, ME, Chute, JP, Gasparetto, C, Long, GD, McDonald, C, Morris, A, Rizzieri, DA, Sullivan, KM, and Chao, NJ. "Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration." Bone Marrow Transplant 47, no. 8 (August 2012): 1051-1055. Full Text Link to Item
  - Giles, FJ, Vey, N, Rizzieri, D, Ravandi, F, Prebet, T, Borthakur, G, Jacobsen, TF, Hagen, S, Nilsson, B, and O'Brien, S. "Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies." Leukemia 26, no. 7 (July 2012): 1686-1689. (Letter) Full Text Link to Item
  - Hale, GA, Shrestha, S, Le-Rademacher, J, Burns, LJ, Gibson, J, Inwards, DJ, Freytes, CO, Bolwell, BJ, Hsu, JW, Slavin, S, Isola, L, Rizzieri, DA, Gale, RP, Laport, GG, Montoto, S, Lazarus, HM, and Hari, PN. "Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR." Biol Blood Marrow Transplant 18, no. 7 (July 2012): 1036-1043.e1. Full Text Link to Item
  - Chen, D-F, Prasad, VK, Broadwater, G, Reinsmoen, NL, DeOliveira, A, Clark, A, Sullivan, KM, Chute, JP, Horwitz, ME, Gasparetto, C, Long, GD, Yang, Y, Chao, NJ, and Rizzieri, DA. "Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors." Bone Marrow Transplant 47, no. 6 (June 2012): 817-823. Full Text Link to Item
  - Khoury, HJ, Kukreja, M, Goldman, JM, Wang, T, Halter, J, Arora, M, Gupta, V, Rizzieri, DA, George, B, Keating, A, Gale, RP, Marks, DI, McCarthy, PL, Woolfrey, A, Szer, J, Giralt, SA, Maziarz, RT, Cortes, J, Horowitz, MM, and Lee, SJ. "Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis." Bone Marrow Transplant 47, no. 6 (June 2012): 810-816. Full Text Link to Item
  - Kanda, J, Horwitz, ME, Long, GD, Gasparetto, C, Sullivan, KM, Chute, JP, Morris, A, Hennig, T, Li, Z, Chao, NJ, and Rizzieri, DA. "Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation." Bone Marrow Transplant 47, no. 5 (May 2012): 700-705. Full Text Link to Item
  - Giles, F, Rizzieri, D, Ravandi, F, Swords, R, Jacobsen, TF, and O'Brien, S. "Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia." Leuk Res 36, no. 4 (April 2012): e71-e73. (Letter) Full Text Link to Item
  - Lanasa, MC, Davis, PH, Datto, M, Li, Z, Gockerman, JP, Moore, JO, DeCastro, CM, Friedman, DR, Diehl, LF, Rehder, C, Cook, H, Daugherty, FJ, Matta, KMB, Weinberg, JB, and Rizzieri, D. "Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia." Leuk Lymphoma 53, no. 2 (February 2012): 218-224. Full Text Link to Item
  - Rizzieri, DA, and Walsh, K. "Chemoimmunotherapy's potential to impact paroxysmal nocturnal hemoglobinuria." Clin Adv Hematol Oncol 10, no. 2 (February 2012): 136-137. (Review) Link to Item
  - Faderl, S, Wetzler, M, Rizzieri, D, Schiller, G, Jagasia, M, Stuart, R, Ganguly, S, Avigan, D, Craig, M, Collins, R, Maris, M, Kovacsovics, T, Goldberg, S, Seiter, K, Hari, P, Greiner, J, Vey, N, Recher, C, Ravandi, F, Wang, ES, Vasconcelles, M, Huebner, D, and Kantarjian, HM. "Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: Results from the CLASSIC I trial." Journal of Clinical Oncology 30, no. 20 (2012): 2492-2499. Full Text
  - Pettengell, R, Coiffier, B, Narayanan, G, Mendoza, FHD, Digumarti, R, Gomez, H, Zinzani, PL, Schiller, G, Rizzieri, D, Boland, G, Cernohous, P, Wang, L, Kuepfer, C, Gorbatchevsky, I, and Singer, JW. "Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: A phase 3, multicentre, open-label, randomised trial." The Lancet Oncology 13, no. 7 (2012): 696-706. Full Text
  - Rao, AV, Rizzieri, DA, DeCastro, CM, Diehl, LF, Lagoo, AS, Moore, JO, and Gockerman, JP. "Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML." Journal of Geriatric Oncology 3, no. 3 (2012): 220-227. Full Text
  - Rizzieri, D, and Moore, JO. "Implementation of management guidelines for chronic myeloidl leukemia perspectives in the United States." P and T 37, no. 11 (2012): 640-648.
  - Farag, SS, Maharry, K, Zhang, M-J, Pérez, WS, George, SL, Mrózek, K, DiPersio, J, Bunjes, DW, Marcucci, G, Baer, MR, Cairo, M, Copelan, E, Cutler, CS, Isola, L, Lazarus, HM, Litzow, MR, Marks, DI, Ringdén, O, Rizzieri, DA, Soiffer, R, Larson, RA, Tallman, MS, Bloomfield, CD, Weisdorf, DJ, and Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B, . "Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission." Biol Blood Marrow Transplant 17, no. 12 (December 2011): 1796-1803. Full Text Link to Item
  - Kelsey, CR, Horwitz, ME, Chino, JP, Craciunescu, O, Steffey, B, Folz, RJ, Chao, NJ, Rizzieri, DA, and Marks, LB. "Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors." Int J Radiat Oncol Biol Phys 81, no. 3 (November 1, 2011): 812-818. Full Text Link to Item
  - Kanda, J, Rizzieri, DA, Gasparetto, C, Long, GD, Chute, JP, Sullivan, KM, Morris, A, Smith, CA, Hogge, DE, Nitta, J, Song, K, Niedzwiecki, D, Chao, NJ, and Horwitz, ME. "Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning." Biol Blood Marrow Transplant 17, no. 6 (June 2011): 867-874. Full Text Link to Item
  - Advani, AS, Gibson, S, Douglas, E, Diacovo, J, Elson, P, Kalaycio, M, Copelan, E, Sekeres, M, Sobecks, R, Sungren, S, Lagoo, A, Rizzieri, D, and Hsi, E. "Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)." Br J Haematol 153, no. 4 (May 2011): 504-507. Full Text Link to Item
  - Kanda, J, Lopez, RD, and Rizzieri, DA. "Alemtuzumab for the prevention and treatment of graft-versus-host disease." Int J Hematol 93, no. 5 (May 2011): 586-593. (Review) Full Text Link to Item
  - Wang, E, Hutchinson, CB, Huang, Q, Lu, CM, Crow, J, Wang, FF, Sebastian, S, Rehder, C, Lagoo, A, Horwitz, M, Rizzieri, D, Yu, J, Goodman, B, Datto, M, and Buckley, P. "Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature." Am J Clin Pathol 135, no. 4 (April 2011): 525-540. (Review) Full Text Link to Item
  - Craciunescu, OI, Steffey, BA, Kelsey, CR, Larrier, NA, Paarz-Largay, CJ, Prosnitz, RG, Chao, N, Chute, J, Gasparetto, C, Horwitz, M, Long, G, Rizzieri, D, and Sullivan, KM. "Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial." Int J Radiat Oncol Biol Phys 79, no. 4 (March 15, 2011): 1248-1255. Full Text Link to Item
  - Kanda, J, Lopez, RD, and Rizzieri, DA. "Alemtuzumab for the prevention and treatment of graft-versus-host disease." International Journal of Hematology (2011): 1-8. Full Text
  - Palmer, J, Goggins, T, Broadwater, G, Chao, N, Horwitz, M, Beaven, A, Sullivan, K, Coleman, RE, and Rizzieri, D. "Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma." Bone Marrow Transplantation 46, no. 6 (2011): 847-851. Full Text
  - Rizzieri, DA, Crout, C, Storms, R, Golob, J, Long, GD, Gasparetto, C, Sullivan, KM, Horwitz, M, Chute, J, Lagoo, AS, Morris, A, Beaven, A, Yang, Y, Peterson, B, Li, Z, and Chao, NJ. "Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors." Cancer Invest 29, no. 1 (January 2011): 56-61. Full Text Link to Item
  - Jima, DD, Zhang, J, Jacobs, C, Richards, KL, Dunphy, CH, Choi, WWL, Au, WY, Srivastava, G, Czader, MB, Rizzieri, DA, Lagoo, AS, Lugar, PL, Mann, KP, Flowers, CR, Bernal-Mizrachi, L, Naresh, KN, Evens, AM, Gordon, LI, Luftig, M, Friedman, DR, Weinberg, JB, Thompson, MA, Gill, JI, Liu, Q, How, T, Grubor, V, Gao, Y, Patel, A, Wu, H, Zhu, J, Blobe, GC, Lipsky, PE, Chadburn, A, Dave, SS, and Hematologic Malignancies Research Consortium, . "Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs." Blood 116, no. 23 (December 2, 2010): e118-e127. Full Text Link to Item
  - Advani, AS, Shadman, M, Ali-Osman, F, Barker, A, Rybicki, L, Kalaycio, M, Sekeres, MA, de Castro, CM, Diehl, LF, Moore, JO, Beaven, A, Copelan, E, Sobecks, R, Talea, P, and Rizzieri, DA. "A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse." Clin Lymphoma Myeloma Leuk 10, no. 6 (December 2010): 473-476. Full Text Link to Item
  - Gupta, V, Tallman, MS, He, W, Logan, BR, Copelan, E, Gale, RP, Khoury, HJ, Klumpp, T, Koreth, J, Lazarus, HM, Marks, DI, Martino, R, Rizzieri, DA, Rowe, JM, Sabloff, M, Waller, EK, DiPersio, JF, Bunjes, DW, and Weisdorf, DJ. "Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis." Blood 116, no. 11 (September 16, 2010): 1839-1848. Full Text Link to Item
  - Kanda, J, Chao, NJ, and Rizzieri, DA. "Haploidentical transplantation for leukemia." Curr Oncol Rep 12, no. 5 (September 2010): 292-301. (Review) Full Text Link to Item
  - Duval, M, Klein, JP, He, W, Cahn, J-Y, Cairo, M, Camitta, BM, Kamble, R, Copelan, E, de Lima, M, Gupta, V, Keating, A, Lazarus, HM, Litzow, MR, Marks, DI, Maziarz, RT, Rizzieri, DA, Schiller, G, Schultz, KR, Tallman, MS, and Weisdorf, D. "Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure." J Clin Oncol 28, no. 23 (August 10, 2010): 3730-3738. Full Text Link to Item
  - Rizzieri, DA, Storms, R, Chen, D-F, Long, G, Yang, Y, Nikcevich, DA, Gasparetto, C, Horwitz, M, Chute, J, Sullivan, K, Hennig, T, Misra, D, Apple, C, Baker, M, Morris, A, Green, PG, Hasselblad, V, and Chao, NJ. "Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation." Biol Blood Marrow Transplant 16, no. 8 (August 2010): 1107-1114. Full Text Link to Item
  - Marks, DI, Wang, T, Pérez, WS, Antin, JH, Copelan, E, Gale, RP, George, B, Gupta, V, Halter, J, Khoury, HJ, Klumpp, TR, Lazarus, HM, Lewis, VA, McCarthy, P, Rizzieri, DA, Sabloff, M, Szer, J, Tallman, MS, and Weisdorf, DJ. "The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission." Blood 116, no. 3 (July 22, 2010): 366-374. Full Text Link to Item
  - Crout, CA, Koh, L-P, Gockerman, JP, Moore, JO, Decastro, C, Long, GD, Diehl, L, Gasparetto, C, Niedzwiecki, D, Edwards, J, Prosnitz, L, Horwitz, M, Chute, J, Morris, A, Davis, P, Beaven, A, Chao, NJ, Ali-Osman, F, and Rizzieri, DA. "Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy." Cancer Invest 28, no. 6 (July 2010): 654-660. Full Text Link to Item
  - Rizzieri, D, LoRusso, S, Tse, W, Khan, K, Advani, A, Moore, J, Karsten, V, Cahill, A, and Gerson, SL. "Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia." Clin Lymphoma Myeloma Leuk 10, no. 3 (June 2010): 211-216. Full Text Link to Item
  - Gasparetto, C, Gockerman, JP, Diehl, LF, de Castro, CM, Moore, JO, Long, GD, Horwitz, ME, Keogh, G, Chute, JP, Sullivan, KM, Neuwirth, R, Davis, PH, Sutton, LM, Anderson, RD, Chao, NJ, and Rizzieri, D. ""Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma." Biol Blood Marrow Transplant 16, no. 1 (January 2010): 70-77. Full Text Link to Item
  - Rao, AV, Valk, PJM, Metzeler, KH, Acharya, CR, Tuchman, SA, Stevenson, MM, Rizzieri, DA, Delwel, R, Buske, C, Bohlander, SK, Potti, A, and Löwenberg, B. "Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia." J Clin Oncol 27, no. 33 (November 20, 2009): 5580-5586. Full Text Link to Item
  - Rizzieri, DA, O'Brien, JA, Broadwater, G, Decastro, CM, Dev, P, Diehl, L, Beaven, A, Lagoo, A, Gockerman, JP, Chao, NJ, and Moore, JO. "Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia." Cancer 115, no. 13 (July 1, 2009): 2922-2929. Full Text Link to Item
  - Nicolini, FE, Alimena, G, Al-Ali, HK, Turkina, AT, Shen, Z, Jootar, S, Smith, G, Conchon, M, Wang, J, Berton, M, Szczudlo, T, and Rizzieri, DA. "EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS (PTS) WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): SUBGROUP ANALYSIS OF PATIENTS WHO FAILED PRIOR DASATINIB THERAPY." HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 94 (June 2009): 257-257. Link to Item
  - Nicolini, FE, Alimena, G, Al-Ali, HK, Turkina, AT, Shen, Z, Jootar, S, Smith, G, De Souza, C, Wang, J, Berton, M, Szczudlo, T, and Rizzieri, DA. "FINAL SAFETY ANALYSIS OF 1,793 CML PATIENTS FROM ENACT (EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA." HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 94 (June 2009): 255-256. Link to Item
  - Prince, HM, Hönemann, D, Spencer, A, Rizzieri, DA, Stadtmauer, EA, Roberts, AW, Bahlis, N, Tricot, G, Bell, B, Demarini, DJ, Benjamin Suttle, A, Baker, KL, and Pandite, LN. "Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)." Blood 113, no. 19 (May 7, 2009): 4819-4820. (Letter) Full Text Link to Item
  - Zhang, J, Jima, DD, Jacobs, C, Fischer, R, Gottwein, E, Huang, G, Lugar, PL, Lagoo, AS, Rizzieri, DA, Friedman, DR, Weinberg, JB, Lipsky, PE, and Dave, SS. "Patterns of microRNA expression characterize stages of human B-cell differentiation." Blood 113, no. 19 (May 7, 2009): 4586-4594. Full Text Link to Item
  - Shea, TC, Beaven, AW, Moore, DT, Serody, JS, Gabriel, DA, Chao, N, Gockerman, JP, Garcia, RA, and Rizzieri, DA. "Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival." Leuk Lymphoma 50, no. 5 (May 2009): 741-748. Full Text Link to Item
  - Zhao, C, Chen, A, Jamieson, CH, Fereshteh, M, Abrahamsson, A, Blum, J, Kwon, HY, Kim, J, Chute, JP, Rizzieri, D, Munchhof, M, VanArsdale, T, Beachy, PA, and Reya, T. "Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia." Nature 458, no. 7239 (April 9, 2009): 776-779. Full Text Link to Item
  - Rizzieri, DA, Dev, P, Long, GD, Gasparetto, C, Sullivan, KM, Horwitz, M, Chute, J, and Chao, NJ. "Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors." Bone Marrow Transplant 43, no. 4 (February 2009): 327-333. Full Text Link to Item
  - Castro, CD, Adams, D, Rizzieri, D, Moore, J, Gockerman, J, Diehl, L, Horwitz, M, Edmonds, E, and Warzecho, J. "P134 A phase II pilot study of sorafenib in patients with myelodysplastic syndromes." Leukemia Research 33, no. SUPPL. 1 (2009): S137-. Full Text
  - Castro, CD, Adams, D, Rizzieri, D, Moore, J, Gockerman, J, Diehl, L, Horwitz, M, Edmonds, E, and Warzecho, J. "P129 A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes." Leukemia Research 33, no. SUPPL. 1 (2009): S134-. Full Text
  - Zhao, C, Chen, A, Jamieson, CH, Fereshteh, M, Abrahamsson, A, Blum, J, Kwon, HY, Kim, J, Chute, JP, Rizzieri, D, Munchhof, M, Vanarsdale, T, Beachy, PA, and Reya, T. "Erratum: Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia (Cancer Cell) (2008) 14 (238-249) DOI:10.1038/nature08255)." Nature 460, no. 7255 (2009): 652--. Full Text
  - Weinberg, JB, Volkheimer, AD, Mihovilovic, M, Jiang, N, Chen, Y, Bond, K, Moore, JO, Gockerman, JP, Diehl, LF, de Castro, CM, Rizzieri, DA, Levesque, MC, Dekroon, R, and Strittmatter, WJ. "Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia." Leukemia 22, no. 12 (December 2008): 2184-2192. Full Text Link to Item
  - Allen, SL, Erba, HP, Rizzieri, DA, O'Donnell, M, Powell, B, Lundberg, AS, Bennett, JM, and Capizzi, RL. "Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML." BLOOD 112, no. 11 (November 16, 2008): 1019-1020. Link to Item
  - Gasparet, C, Gockerman, JP, Diehl, LF, III, DCC, Moore, J, Long, GD, Horwitz, M, Chute, J, Sullivan, KM, Netuwirth, R, Davis, PH, Sutton, LM, Anderson, RD, Chao, N, and Rizzieri, DA. "Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma." BLOOD 112, no. 11 (November 16, 2008): 1142-1142. Link to Item
  - O'Brien, S, Rizzieri, DA, Vey, N, Kantarjian, HM, Jacobsen, TF, Nilsson, BI, Staudacher, K, and Giles, F. "A Phase I/II Study with CP-4055 in Patients with Haematologic Malignancies." BLOOD 112, no. 11 (November 16, 2008): 350-350. Link to Item
  - Prasad, VK, Chen, D-F, Broadwater, G, Reinsmoen, NL, Clark, A, Chao, NJ, and Rizzieri, DA. "Differential Impact of Inhibitory and Activating Killer Ig-Like Receptors and HLA Ligand on Outcomes of Transplantation for Myeloid and Lymphoid Malignancies." BLOOD 112, no. 11 (November 16, 2008): 1118-1118. Link to Item
  - Rao, AV, Tuchman, SA, Potti, A, Rizzieri, DA, Mano, H, Delwel, R, Valk, P, and Lowenberg, B. "Gene Expression Profiles with Signatures of Tumor Biology and Chemotherapy Sensitivity May Provide a Novel Approach to Maximize Response to Induction Therapy in Patients with Acute Myeloid Leukemia." BLOOD 112, no. 11 (November 16, 2008): 785-786. Link to Item
  - Rizzieri, DA, Storms, R, Nikcevich, D, Peterson, B, Misra, D, Apple, C, Baker, M, Gasparetto, C, Horwitz, M, Chute, J, Morris, A, and Chao, NJ. "Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation." BLOOD 112, no. 11 (November 16, 2008): 133-134. Link to Item
  - Zhang, J, Jima, DD, Jacobs, CL, Gottwein, E, Huang, G, Lugar, PL, Lagoo, AS, Rizzieri, DA, Lipsky, PE, and Dave, SS. "MicroRNAs Regulate Mature B Cell Differentiation." BLOOD 112, no. 11 (November 16, 2008): 262-262. Link to Item
  - Lee, SJ, Kukreja, M, Wang, T, Giralt, SA, Szer, J, Arora, M, Woolfrey, AE, Cervantes, F, Champlin, RE, Gale, RP, Halter, J, Keating, A, Marks, DI, McCarthy, PL, Olavarria, E, Stadtmauer, EA, Abecasis, M, Gupta, V, Khoury, HJ, George, B, Hale, GA, Liesveld, JL, Rizzieri, DA, Antin, JH, Bolwell, BJ, Carabasi, MH, Copelan, E, Ilhan, O, Litzow, MR, Schouten, HC, Zander, AR, Horowitz, MM, and Maziarz, RT. "Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia." Blood 112, no. 8 (October 15, 2008): 3500-3507. Full Text Link to Item
  - Rao, AV, Younis, IR, Sand, GJ, Spasojevic, I, Adams, DJ, Decastro, CM, Gockerman, JP, Peterson, BL, Petros, WP, Moore, JO, and Rizzieri, DA. "Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia." Leuk Lymphoma 49, no. 8 (August 2008): 1523-1529. Full Text Link to Item
  - Nicolini, FE, Alimena, G, Al-Ali, H, Zaritskey, AY, Shen, Z, Jootar, S, Smith, G, Hsu, Y, Veronese, ML, and Rizzieri, DA. "Expanding Nilotinib Access in Clinical Trials (ENACT) study in adult patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph plus ) chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP), or blast crisis (BC): Updated safety analysis." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008). Link to Item
  - O'Brien, SM, Vey, N, Rizzieri, DA, Kantarjian, HM, Prebet, T, Ravandi, F, Jacobsen, TF, Nilsson, BI, Staudacher, K, and Giles, FJ. "A phase I study with CP-4055 in patients with hematologic malignancies." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008). Link to Item
  - Rizzieri, DA, Erba, HP, O'Donnell, M, Powell, BL, Lundberg, AS, Bennett, JM, and Capizzi, RL. "Amonafide plus ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008). Link to Item
  - Horwitz, ME, Morris, A, Gasparetto, C, Sullivan, K, Long, G, Chute, J, Rizzieri, D, McPherson, J, and Chao, N. "Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients." Biol Blood Marrow Transplant 14, no. 5 (May 2008): 591-594. Full Text Link to Item
  - Rizzieri, DA, Feldman, E, Dipersio, JF, Gabrail, N, Stock, W, Strair, R, Rivera, VM, Albitar, M, Bedrosian, CL, and Giles, FJ. "A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies." Clin Cancer Res 14, no. 9 (May 1, 2008): 2756-2762. Full Text Link to Item
  - Adams, DJ, Sandvold, ML, Myhren, F, Jacobsen, TF, Giles, F, and Rizzieri, DA. "Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells." Leuk Lymphoma 49, no. 4 (April 2008): 786-797. Full Text Link to Item
  - Byrne, BJ, Horwitz, M, Long, GD, Gasparetto, C, Sullivan, KM, Chute, J, Chao, NJ, and Rizzieri, DA. "Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection." Bone Marrow Transplant 41, no. 1 (January 2008): 39-43. Full Text Link to Item
  - Frankel, A, Liu, J-S, Rizzieri, D, and Hogge, D. "Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia." Leukemia and Lymphoma 49, no. 3 (2008): 543-553. Full Text
  - Hobeika, A, Osada, T, Serra, D, Peplinski, S, Hanson, K, Tanaka, Y, Niedzwiecki, D, Chao, N, Rizzieri, D, Lyerly, H, Clay, T, and Morse, M. "Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease." Cytotherapy 10, no. 3 (2008): 289-302. Full Text Link to Item
  - Smith, SM, Grinblatt, D, Johnson, JL, Niedzwiecki, D, Rizzieri, D, Bartlett, NL, and Cheson, BD. "Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: A phase II trial of the Cancer and Leukemia Group B." British Journal of Haematology 140, no. 3 (2008): 313-319. Full Text
  - Horwitz, ME, Spasojevic, I, Morris, A, Telen, M, Essell, J, Gasparetto, C, Sullivan, K, Long, G, Chute, J, Chao, N, and Rizzieri, D. "Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics." Biol Blood Marrow Transplant 13, no. 12 (December 2007): 1422-1426. Full Text Link to Item
  - Weinberg, JB, Volkheimer, AD, Chen, Y, Beasley, BE, Jiang, N, Lanasa, MC, Friedman, D, Vaccaro, G, Rehder, CW, Decastro, CM, Rizzieri, DA, Diehl, LF, Gockerman, JP, Moore, JO, Goodman, BK, and Levesque, MC. "Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia." Am J Hematol 82, no. 12 (December 2007): 1063-1070. Full Text Link to Item
  - Koh, L-P, Rizzieri, DA, and Chao, NJ. "Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors." Biol Blood Marrow Transplant 13, no. 11 (November 2007): 1249-1267. (Review) Full Text Link to Item
  - Rizzieri, DA, Koh, LP, Long, GD, Gasparetto, C, Sullivan, KM, Horwitz, M, Chute, J, Smith, C, Gong, JZ, Lagoo, A, Niedzwiecki, D, Dowell, JM, Waters-Pick, B, Liu, C, Marshall, D, Vredenburgh, JJ, Gockerman, J, Decastro, C, Moore, J, and Chao, NJ. "Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution." J Clin Oncol 25, no. 6 (February 20, 2007): 690-697. Full Text Link to Item
  - Giles, F, Rizzieri, D, Karp, J, Vey, N, Ravandi, F, Faderl, S, Khan, KD, Verhoef, G, Wijermans, P, Advani, A, Roboz, G, Kantarjian, H, Bilgrami, SFA, Ferrant, A, Daenen, SMGJ, Karsten, V, Cahill, A, Albitar, M, Mufti, G, and O'Brien, S. "Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia." J Clin Oncol 25, no. 1 (January 1, 2007): 25-31. Full Text Link to Item
  - Lagoo, AS, Gong, JZ, Stenzel, TT, Goodman, BK, Buckley, PJ, Chao, NJ, Gasparetto, C, Long, GD, and Rizzieri, DA. "Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment." Arch Pathol Lab Med 130, no. 10 (October 2006): 1479-1488. Full Text Link to Item
  - Vredenburgh, JJ, Coniglio, D, Broadwater, G, Jones, RB, Ross, M, Shpall, EJ, Hussein, A, Rizzieri, D, Marks, LB, Gilbert, C, Affronti, ML, Moore, S, McDonald, C, Petros, WP, and Peters, WP. "Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone." Biol Blood Marrow Transplant 12, no. 2 (February 2006): 195-203. Full Text Link to Item
  - Schiller, GJ, Slack, J, Hainsworth, JD, Mason, J, Saleh, M, Rizzieri, D, Douer, D, and List, AF. "Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes." Journal of Clinical Oncology 24, no. 16 (2006): 2456-2464. Full Text
  - Dannull, J, Su, Z, Rizzieri, D, Yang, BK, Coleman, D, Yancey, D, Zhang, A, Dahm, P, Chao, N, Gilboa, E, and Vieweg, J. "Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells." J Clin Invest 115, no. 12 (December 2005): 3623-3633. Full Text Link to Item
  - Rizzieri, DA, Wadleigh, M, Wikstrand, CJ, Mann, KP, Sen, F, Peterson, BL, Niedzwiecki, D, Proia, AD, and Bigner, DD. "Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity." Leuk Lymphoma 46, no. 10 (October 2005): 1455-1462. Full Text Link to Item
  - Rao, AV, Akabani, G, and Rizzieri, DA. "Radioimmunotherapy for Non-Hodgkin's Lymphoma." Clin Med Res 3, no. 3 (August 2005): 157-165. (Review) Link to Item
  - Shanks, RH, Rizzieri, DA, Flowers, JL, Colvin, OM, and Adams, DJ. "Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia." Clin Cancer Res 11, no. 11 (June 1, 2005): 4225-4233. Full Text Link to Item
  - Nieto, Y, Vredenburgh, JJ, Shpall, EJ, Bearman, SI, McSweeney, PA, Chao, N, Rizzieri, D, Gasparetto, C, Matthes, S, Barón, AE, and Jones, RB. "Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer." Clin Cancer Res 10, no. 21 (November 1, 2004): 7136-7143. Full Text Link to Item
  - Talbot, J, Ibom, VK, Rizzieri, DA, Barrier, R, Niedzwieki, D, DeCastro, CM, Moore, JO, Buckley, P, Laney, R, Stevenson, D, Rumbaugh, H, and Gockerman, JP. "Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma." Clin Lymphoma 5, no. 2 (September 2004): 116-122. Link to Item
  - Bhagat, R, Rizzieri, DA, Vredenburgh, JJ, Chao, NJ, and Folz, RJ. "Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?." Chest 126, no. 2 (August 2004): 642-644. Full Text Link to Item
  - Chao, NJ, Koh, L-P, Long, GD, Gasparetto, C, Horwitz, M, Morris, A, Lassiter, M, Sullivan, KM, and Rizzieri, DA. "Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens." Biol Blood Marrow Transplant 10, no. 8 (August 2004): 569-575. Full Text Link to Item
  - Rizzieri, DA, Akabani, G, Zalutsky, MR, Coleman, RE, Metzler, SD, Bowsher, JE, Toaso, B, Anderson, E, Lagoo, A, Clayton, S, Pegram, CN, Moore, JO, Gockerman, JP, DeCastro, C, Gasparetto, C, Chao, NJ, and Bigner, DD. "Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma." Blood 104, no. 3 (August 1, 2004): 642-648. Full Text Link to Item
  - Rizzieri, DA, Sand, GJ, McGaughey, D, Moore, JO, DeCastro, C, Chao, NJ, Vredenburgh, JJ, Gasparetto, C, Long, GD, Anderson, E, Foster, T, Toaso, B, Adams, D, Niedzwiecki, D, and Gockerman, JP. "Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma." Cancer 100, no. 11 (June 1, 2004): 2408-2414. Full Text Link to Item
  - Snyder, MJ, Stenzel, TT, Buckley, PJ, Lagoo, AS, Rizzieri, DA, Gasparetto, C, Vredenburgh, JJ, Chao, NJ, and Gong, JZ. "Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation." Am J Surg Pathol 28, no. 6 (June 2004): 794-800. Link to Item
  - Rizzieri, DA, Johnson, JL, Niedzwiecki, D, Lee, EJ, Vardiman, JW, Powell, BL, Barcos, M, Bloomfield, CD, Schiffer, CA, Peterson, BA, Canellos, GP, and Larson, RA. "Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251." Cancer 100, no. 7 (April 1, 2004): 1438-1448. Full Text Link to Item
  - Gasparetto, M, Gentry, T, Sebti, S, O'Bryan, E, Nimmanapalli, R, Blaskovich, MA, Bhalla, K, Rizzieri, D, Haaland, P, Dunne, J, and Smith, C. "Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening." Journal of Immunological Methods 292, no. 1-2 (2004): 59-71. Full Text
  - Goggins, TF, and Rizzieri, DA. "Nonmyeloablative Allogeneic Stem Cell Transplantation Using Alternative Donors." Cancer Control 11, no. 2 (2004): 86-96.
  - Rizzieri, DA, Weitman, S, and Vaughn, DM. "An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab." NEW ENGLAND JOURNAL OF MEDICINE 349, no. 26 (December 25, 2003): 2571-2572. Link to Item
  - Long, GD, Laughlin, M, Madan, B, Kurtzberg, J, Gasparetto, C, Morris, A, Rizzieri, D, Smith, C, Vredenburgh, J, Halperin, EC, Broadwater, G, Niedzwiecki, D, and Chao, NJ. "Unrelated umbilical cord blood transplantation in adult patients." Biol Blood Marrow Transplant 9, no. 12 (December 2003): 772-780. Full Text Link to Item
  - Ibom, VK, Prosnitz, RG, Gong, JZ, Moore, JO, DeCastro, CM, Prosnitz, LR, Rizzieri, DA, and Gockerman, JP. "Rituximab in lymphocyte predominance Hodgkin's disease: a case series." Clin Lymphoma 4, no. 2 (September 2003): 115-118. Link to Item
  - Talbot, J, Rizzieri, DA, DeCastro, CM, Moore, JO, Buckley, P, Laney, R, Stevenson, D, Brumbaugh, H, and Gockerman, JP. "High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series." Am J Hematol 73, no. 4 (August 2003): 295-296. (Letter) Full Text Link to Item
  - Gong, JZ, Stenzel, TT, Bennett, ER, Lagoo, AS, Dunphy, CH, Moore, JO, Rizzieri, DA, Tepperberg, JH, Papenhausen, P, and Buckley, PJ. "Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases." Am J Surg Pathol 27, no. 6 (June 2003): 818-827. Link to Item
  - Rizzieri, DA, Talbot, JT, Long, GD, Vredenburgh, JJ, Gasparetto, C, Smith, CS, Colvin, MO, Adams, D, Morris, A, Dodge, R, Loftis, J, Waters-Pick, B, Reese, M, Carawan, H, Koh, LP, and Chao, NJ. "4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia." Biol Blood Marrow Transplant 9, no. 3 (March 2003): 183-188. Full Text Link to Item
  - Rizzieri, DA, Ibom, VK, Moore, JO, DeCastro, CM, Rosner, GL, Adams, DJ, Foster, T, Payne, N, Thompson, M, Vredenburgh, JJ, Gasparetto, C, Long, GD, Chao, NJ, and Gockerman, JP. "Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia." Clin Cancer Res 9, no. 2 (February 2003): 663-668. Link to Item
  - Ghobrial, IM, Otteman, LA, White, WL, Rizzieri, DA, Weitman, S, and Vaughn, DM. "An EBV-Positive Lymphoproliferative Disorder after Therapy with Alemtuzumab [6] (multiple letters)." New England Journal of Medicine 349, no. 26 (2003): 2570-2572. Full Text
  - Morse, MA, Rizzieri, D, Stenzel, TT, Hobeika, AC, Vredenburgh, JJ, Chao, NJ, Clay, TM, Mosca, PJ, and Lyerly, HK. "Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants." J Hematother Stem Cell Res 11, no. 4 (August 2002): 659-668. Full Text Link to Item
  - Bass, AJ, Gockerman, JP, Hammett, E, DeCastro, CM, Adams, DJ, Rosner, GL, Payne, N, Davis, P, Foster, T, Moore, JO, and Rizzieri, DA. "Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma." J Clin Oncol 20, no. 13 (July 1, 2002): 2995-3000. Full Text Link to Item
  - McCune, SL, Gockerman, JP, Moore, JO, Decastro, CM, Bass, AJ, Chao, NJ, Long, GD, Vredenburgh, JJ, Gasparetto, C, Adams, D, Payne, N, and Rizzieri, DA. "Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia." Leuk Lymphoma 43, no. 5 (May 2002): 1007-1011. Full Text Link to Item
  - Gasparetto, C, Gasparetto, M, Morse, M, Rooney, B, Vredenburgh, JJ, Long, GD, Rizzieri, DA, Loftis, J, Chao, NJ, and Smith, C. "Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF." Cytokine 18, no. 1 (April 7, 2002): 8-19. Link to Item
  - Chao, NJ, Rizzieri, DA, Long, GD, Vredenburgh, JJ, Gasparetto, C, Morris, A, and Davis, P. "Allogeneic engraftment of mismatched unrelated cord blood following a non-myeloablative preparative regimen." LEUKEMIA 16, no. 3 (March 2002): 407-407. Link to Item
  - Bass, AJ, Gong, J, Nelson, R, and Rizzieri, DA. "CD52 expression in mantle cell lymphoma." Leuk Lymphoma 43, no. 2 (February 2002): 339-342. Full Text Link to Item
  - Rizzieri, DA, Bass, AJ, Rosner, GL, Gockerman, JP, DeCastro, CM, Petros, WP, Adams, DJ, Laughlin, MJ, Davis, P, Foster, T, Jacobson, R, Hurwitz, H, and Moore, JO. "Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia." J Clin Oncol 20, no. 3 (February 1, 2002): 674-679. Full Text Link to Item
  - Chao, NJ, Liu, CX, Rooney, B, Chen, BJ, Long, GD, Vredenburgh, JJ, Morris, A, Gasparetto, C, and Rizzieri, DA. "Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells." Biol Blood Marrow Transplant 8, no. 5 (2002): 249-256. Link to Item
  - Stuart, MJ, Peters, WP, Broadwater, G, Hussein, A, Ross, M, Marks, LB, Folz, RJ, Long, GD, Rizzieri, D, Chao, NJ, and Vredenburgh, JJ. "High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes." Biology of Blood and Marrow Transplantation 8, no. 12 (2002): 666-673. Full Text
  - Rizzieri, DA, Long, GD, Vredenburgh, JJ, Gasparetto, C, Morris, A, Stenzel, TT, Davis, P, and Chao, NJ. "Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen." Blood 98, no. 12 (December 1, 2001): 3486-3488. Link to Item
  - Bass, A, Moore, JO, DeCastro, C, Gockerman, JP, Rosner, G, Payne, N, Foster, T, Hammett, E, Adams, D, Long, G, Gasparetto, C, Vredenburgh, JJ, Chao, NJ, and Rizzieri, DA. "Prolonged infusion gemcitabine in combination with CPT-11 for relapsed or refractory hematologic malignancies." BLOOD 98, no. 11 (November 16, 2001): 209B-209B. Link to Item
  - Gandy, KL, Chao, NJ, Gasparetto, C, Long, GD, Reinsmoen, NL, and Rizzieri, DA. "PRA reduction after sublethal preconditioning and hematopoietic reconstitution with Campath-1-treated mobilized peripheral blood." BLOOD 98, no. 11 (November 16, 2001): 315B-315B. Link to Item
  - Guzman, ML, Neering, SJ, Swiderski, C, Grimes, B, Howard, DS, Rizzieri, DA, and Jordan, CT. "Unique molecular characteristics of primitive human AML cells permit apoptosis to be specifically induced in leukemic but not normal stem cells." BLOOD 98, no. 11 (November 16, 2001): 93A-93A. Link to Item
  - Klein, AK, Qumsiyeh, MB, Hayes, N, Long, GD, Vredenburgh, JJ, Rizzieri, DA, Gasparetto, C, and Chao, NJ. "Translocations of the MLL gene can be detected in an increased proportion of mononuclear cells collected after etoposide priming in patients subsequently developing secondary acute leukemia." BLOOD 98, no. 11 (November 16, 2001): 401A-402A. Link to Item
  - Lagoo, AS, Gong, JZ, Rizzieri, DA, Stenzel, TT, Chao, NJ, and Buckley, PJ. "Molecular evidence of engraftment in bone marrow after nonmyeloablative allogeneic stem cell transplant (NMASCT) is an unreliable indicator of residual/recurrent disease in the marrow." BLOOD 98, no. 11 (November 16, 2001): 185A-185A. Link to Item
  - McCune, SL, Gockerman, JP, Moore, JO, deCastro, CM, Bass, AJ, Chao, NJ, Long, GD, Vredenburgh, JJ, Gasparetto, C, Adams, DB, Payne, NP, and Rizzieri, DA. "Alemtuzumab (Campath) in relapsed or refractory CLL or PLL." BLOOD 98, no. 11 (November 16, 2001): 290B-291B. Link to Item
  - Rizzieri, DA, Akabani, G, Coleman, RE, Zalutsky, MR, Niedzwiecki, D, Payne, N, Wikstrand, C, and Bigner, DD. "Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma (NHL)." BLOOD 98, no. 11 (November 16, 2001): 247B-247B. Link to Item
  - Rizzieri, DA, DeCastro, C, Gockerman, JP, Niedzwiecki, D, Vredenburgh, JJ, Gasparetto, C, Long, G, Payne, N, Ibom, V, Chao, NJ, and Moore, JO. "Low dose, weekly, paclitaxel as salvage therapy for non-Hodgkins lymphoma (NHL)." BLOOD 98, no. 11 (November 16, 2001): 246B-246B. Link to Item
  - Rizzieri, DA, Gockerman, JP, Moore, JO, DeCastro, C, Long, GD, Vredenburgh, JJ, Niedzwiecki, D, Edwards, J, Prosnitz, L, Gasparetto, C, Morris, A, Lassiter, M, Davis, P, and Chao, NJ. "Dose dense, high intensity therapy for mantle cell lymphoma." BLOOD 98, no. 11 (November 16, 2001): 681A-682A. Link to Item
  - Rizzieri, DA, Ibom, V, DeCastro, C, Moore, JO, Payne, N, Adams, D, Adams, DJ, Rosner, G, Vredenburgh, JJ, Gasparetto, C, Long, G, Chao, NJ, and Gockerman, JP. "Phase I trial of prolonged infusion gemcitabine with fludarabine for relapsed/refractory acute leukemia." BLOOD 98, no. 11 (November 16, 2001): 220B-221B. Link to Item
  - Rizzieri, DA, Long, GD, Vredenburgh, JJ, Gasparetto, C, Morris, A, Lassiter, M, Loftis, J, Davis, P, McDonald, C, Stenzel, T, Niedzwiecki, D, and Chao, NJ. "Non-myeloablative allogeneic transplantation using T depleted matched sibling peripheral blood stem cells." BLOOD 98, no. 11 (November 16, 2001): 420A-421A. Link to Item
  - Rizzieri, DA, Long, GD, Vredenburgh, JJ, Gasparetto, C, Morris, A, Lassiter, M, Loftis, J, Davis, P, McDonald, C, Stenzel, T, Niedzwiecki, D, and Chao, NJ. "Non-myeloablative transplantation using CAMPATH 1H for T depletion of mismatched, related donor peripheral blood stem cells." BLOOD 98, no. 11 (November 16, 2001): 669A-669A. Link to Item
  - Rizzieri, DA, Long, GD, Vredenburgh, JJ, Gasparetto, C, Morris, A, Niedzwiecki, D, Lassiter, M, Loftis, J, Davis, P, McDonald, C, Stenzel, T, Waters-Pick, B, Kurtzberg, J, and Chao, NJ. "Durable engraftment of mismatched unrelated cord blood following a non-myeloablative preparative regimen for adults." BLOOD 98, no. 11 (November 16, 2001): 185A-185A. Link to Item
  - Wadleigh, M, Niedzwiecki, D, Davis, P, Payne, N, Sen, F, Mann, KP, Proia, A, Hollis, D, and Rizzieri, DA. "Increased microvessel density in non-Hodgkin's lymphoma (NHL) is localized to the site of disease changes in accordance with disease response." BLOOD 98, no. 11 (November 16, 2001): 236B-236B. Link to Item
  - Guzman, ML, Neering, SJ, Upchurch, D, Grimes, B, Howard, DS, Rizzieri, DA, Luger, SM, and Jordan, CT. "Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells." Blood 98, no. 8 (October 15, 2001): 2301-2307. Link to Item
  - McCune, SL, Gockerman, JP, and Rizzieri, DA. "Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma." JAMA 286, no. 10 (September 12, 2001): 1149-1152. (Review) Link to Item
  - Laughlin, MJ, Barker, J, Bambach, B, Koc, ON, Rizzieri, DA, Wagner, JE, Gerson, SL, Lazarus, HM, Cairo, M, Stevens, CE, Rubinstein, P, and Kurtzberg, J. "Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors." N Engl J Med 344, no. 24 (June 14, 2001): 1815-1822. Full Text Link to Item
  - Guzman, ML, Upchurch, D, Grimes, B, Howard, DS, Rizzieri, DA, Luger, SM, Phillips, GL, and Jordan, CT. "Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells." Blood 97, no. 7 (April 1, 2001): 2177-2179. Link to Item
  - Gong, JZ, Lagoo, AS, Rizzieri, DA, Stenzel, TT, Chao, NJ, and Buckley, PJ. "Serial morphologic changes in the bone arrow after non-myeloablative allogenic "mini-allogenic" stem cell transplant (NMASCT): correlation with engraftment." LABORATORY INVESTIGATION 81, no. 1 (January 2001): 164A-164A. Link to Item
  - Gong, JZ, Lagoo, AS, Rizzieri, DA, Stenzel, TT, Chao, NJ, and Buckley, PJ. "Serial morphologic changes in the bone marrow after nonmyeloablative allogenic "mini-allogenic" stem cell transplant (NMASCT): correlation with engraftment." MODERN PATHOLOGY 14, no. 1 (January 2001): 164A-164A. Link to Item
  - McGaughey, DS, Nikcevich, DA, Long, GD, Vredenburgh, JJ, Rizzieri, D, Smith, CA, Broadwater, G, Loftis, JS, McDonald, C, Morris, AK, Folz, RF, and Chao, NF. "Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation." Biol Blood Marrow Transplant 7, no. 5 (2001): 274-278. Link to Item
  - Rizzieri, DA, Gockerman, JP, Decastro, CM, Lilly, S, and Foster, T. "Phase i trial of continuously infused gemcitabine with cpt-11 for refractory hematologic malignancies." Blood 96, no. 11 PART II (2001): 216b-.
  - Guzman, HL, Upchurch, D, Grimes, B, Howard, DS, Phillips, GL, Rizzieri, DA, Luger, SM, and Jordan, CT. "Induction of apoptosis in primitive human AML cells using the proteasome inhibitor MG-132 and/or sodium salicylate." BLOOD 96, no. 11 (November 16, 2000): 80A-80A. Link to Item
  - Guzman, ML, Upchurch, D, Grimes, B, Howard, DS, Phillips, GL, Rizzieri, DA, Luger, SM, and Jordan, CT. "Expression of tumor suppressor genes IRF-1 and DAP-kinase in primitive AML cells." BLOOD 96, no. 11 (November 16, 2000): 696A-696A. Link to Item
  - Laughlin, MJ, Barker, J, Bambach, B, Koc, ON, Rizzieri, DA, Wagner, JE, Gerson, SL, Lazarus, HM, Cairo, M, Stevens, CE, Rubinstein, P, and Kurtzberg, J. "Hematopoietic engraftment and survival after unrelated donor umbilical cord blood (UCB) transplantation in adult recipients." BLOOD 96, no. 11 (November 16, 2000): 587A-+. Link to Item
  - Rizzieri, DA, Gockerman, JP, DeCastro, CM, Petros, WP, Lilly, S, Davis, PH, Foster, T, Jarrell, E, Laughlin, MJ, Adams, DJ, and Moore, JO. "Phase I trial of continuously infused gemcitabine with mitoxantrone for high risk or relapsed acute leukemia." BLOOD 96, no. 11 (November 16, 2000): 326A-326A. Link to Item
  - Rizzieri, DA, Gockerman, JP, Decastro, CM, Lilly, S, Foster, T, Adams, D, and Moore, JO. "Phase I trial of continuously infused gemcitabine with CPT-11 for refractory hematologic malignancies." BLOOD 96, no. 11 (November 16, 2000): 216B-216B. Link to Item
  - Rizzieri, DA, Long, GD, Gasparetto, C, Smith, CS, Vredenburgh, JJ, Morris, AK, Petros, WP, Loftis, J, McDonald, CS, Waters-Pick, B, Adams, DJ, and Chao, NJ. "Phase I trial of escalting doses of 4-hydroxycyclophosphamide (4HC) purged autologous peripheral blood progenitor cells (PBPC) for leukemia." BLOOD 96, no. 11 (November 16, 2000): 385A-385A. Link to Item
  - Rizzieri, DA, Long, GD, Vredenburgh, JJ, Gasparetto, C, Smith, CS, Morris, AK, Petros, WP, Davis, PH, Lassiter, ME, Waters-Pick, BA, and Chao, NJ. "Chimerism mediated immunotherapy using Campath T cell depleted peripheral blood progenitor cells (PBPC) with nonablative therapy provides reliable, durable allogeneic engraftment." BLOOD 96, no. 11 (November 16, 2000): 521A-521A. Link to Item
  - Elconin, JH, Roberts, KB, Rizzieri, DA, Vermont, C, Clough, RW, Kim, C, Dodge, RK, and Prosnitz, LR. "Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy." Int J Radiat Oncol Biol Phys 48, no. 4 (November 1, 2000): 1097-1105. Link to Item
  - Jordan, CT, Upchurch, D, Szilvassy, SJ, Guzman, ML, Howard, DS, Pettigrew, AL, Meyerrose, T, Rossi, R, Grimes, B, Rizzieri, DA, Luger, SM, and Phillips, GL. "The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells." Leukemia 14, no. 10 (October 2000): 1777-1784. Link to Item
  - Jordan, CT, Phillips, GL, Rizzieri, DA, Luger, SM, Grimes, B, and Upchurch, D. "Cell cycle analyses and apoptosis in primitive leukemic and normal cells." BLOOD 94, no. 10 (November 15, 1999): 687A-687A. Link to Item
  - Jordan, CT, Rizzieri, DA, Upchurch, D, Grimes, B, and Phillips, GL. "The interleukin-3 receptor alpha chain is highly expressed on primitive acute myelogenous leukemia cells." BLOOD 94, no. 10 (November 15, 1999): 67A-67A. Link to Item
  - Howard, DS, Rizzieri, DA, Grimes, B, Upchurch, D, Phillips, GL, Stewart, AK, Yannelli, JR, and Jordan, CT. "Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer." LEUKEMIA 13, no. 10 (October 1999): 1608-1616. Link to Item
  - Rizzieri, DA, Vredenburgh, JJ, Jones, R, Ross, M, Shpall, EJ, Hussein, A, Broadwater, G, Berry, D, Petros, WP, Gilbert, C, Affronti, ML, Coniglio, D, Rubin, P, Elkordy, M, Long, GD, Chao, NJ, and Peters, WP. "Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support." J Clin Oncol 17, no. 10 (October 1999): 3064-3074. Full Text Link to Item
  - Rizzieri, DA, Vredenburgh, JJ, Chao, NJ, Broadwater, G, Berry, D, and Peters, WP. "Long term disease free survival for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high dose therapy with hematopoietic support." BLOOD 92, no. 10 (November 15, 1998): 323A-323A. Link to Item
  - Rizzieri, DA, Vredenburgh, JJ, Chao, NJ, Broadwater, G, Berry, D, and Peters, WP. "Prognostic factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high dose therapy with hematopoietic support." BLOOD 92, no. 10 (November 15, 1998): 462A-463A. Link to Item
  - Laughlin, MJ, McGaughey, DS, Crews, JR, Chao, NJ, Rizzieri, D, Ross, M, Gockerman, J, Cirrincione, C, Berry, D, Mills, L, Defusco, P, LeGrand, S, Peters, WP, and Vredenburgh, JJ. "Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant." J Clin Oncol 16, no. 3 (March 1998): 1008-1012. Full Text Link to Item
  - Laughlin, MJ, Rizzieri, DA, Smith, CA, Moore, JO, Lilly, S, McGaughey, D, Martin, P, Carrier, C, Stevens, CE, Rubinstein, P, Buckley, R, and Kurtzberg, J. "Hematologic engraftment and reconstitution of immune function post unrelated placental cord blood transplant in an adult with acute lymphocytic leukemia." Leuk Res 22, no. 3 (March 1998): 215-219. Link to Item
  - Kurtzberg, J, Laughlin, MJ, Smith, CA, Rizzieri, DA, Vredenburgh, JJ, Lassiter, ME, Affronti, ML, Coniglio, DM, Carrier, C, Stevens, CE, Rubinstein, P, and Chao, NJ. "Hematopoietic recovery in adult recipients following unrelated umbilical cord blood (UCB) transplantation." BLOOD 90, no. 10 (November 15, 1997): 480-480. Link to Item
  - Rizzieri, DA, and Chao, NJ. "Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell support." Curr Opin Oncol 9, no. 5 (September 1997): 420-427. (Review) Link to Item
  - Rizzieri, DA, Liu, J, Miralles, D, and Traweek, ST. "Kaposi's-sarcoma-associated herpesvirus is detected in peripheral blood mononuclear cells of HIV-infected homosexuals more often than in heterosexuals." Cancer J Sci Am 3, no. 3 (May 1997): 153-156. Link to Item
  - Rizzieri, DA, and Gockerman, JP. "Thrombocytosis associated with low-molecular-weight heparin - Response." ANNALS OF INTERNAL MEDICINE 126, no. 9 (May 1, 1997): 742-743. Link to Item
  - Rizzieri, DA, Liu, J, Traweek, ST, and Miralles, GD. "Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor." Lancet 349, no. 9054 (March 15, 1997): 775-776. (Letter) Full Text Link to Item
  - Williams, E, Rizzieri, DA, and Gockerman, JP. "Thrombocytosis associated with low-molecular-weight heparin [6] (multiple letters)." Annals of Internal Medicine 126, no. 9 (1997): 742-743.
  - Rizzieri, DA, Liu, J, Miralles, D, and Traweek, ST. "Increased prevalence of Kaposi's sarcoma-associated herpesvirus in peripheral blood mononuclear cells of HIV-infected homosexuals." BLOOD 88, no. 10 (November 15, 1996): 1992-1992. Link to Item
  - Rizzieri, DA, Wong, WM, and Gockerman, JP. "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125, no. 2 (July 15, 1996): 157-. (Letter) Link to Item
  - RIZZIERI, DA. "CAUSES OF RHABDOMYOLYSIS - RESPONSE." MAYO CLINIC PROCEEDINGS 70, no. 12 (December 1995): 1225-1225. Link to Item
  - Rizzieri, DA, DeCastro, CM, Mann, KP, and Moore, JO. "T cell lymphoblastic leukemia with mediastinal mass and c-kit expression." BLOOD 86, no. 10 (November 15, 1995): 3095-3095. Link to Item
  - Rizzieri, DA. "Rhabdomyolysis after correction of hyponatremia due to psychogenic polydipsia." Mayo Clin Proc 70, no. 5 (May 1995): 473-476. Full Text Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Grants

Selected Publications

Conference Papers

Journal Articles